General References

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

H
Ha E, Choe BK, Jung KH et al. Positive relationship between melatonin receptor type 1B polymorphism and rheumatoid factor in rheumatoid arthritis patients in the Korean population. J Pineal Res 2005; 39:201-5.

Ha HR, Candinas R, Stieger B, Meyer UA, Follath F. Interaction between amiodarone and lidocaine. J Cardiovasc Pharmacol 1996; 28:533-9.

Ha HR, Chen J, Freiburghaus AU, Follath F. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995; 39:321-6.

Ha HR, Chen J, Krahenbuhl S, Follath F. Biotransformation of caffeine by cDNA-expressed human cytochromes P-450. Eur J Clin Pharmacol 1996; 49:309-15.

Haakensen VD, Bjøro T, Lüders T et al. Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas. BMC Cancer 2011; 11:332.

Haas CE, Brazeau D, Cloen D et al. Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction. Eur J Clin Pharmacol 2005; 61:583-93.

Haas CE, Kaufman DC, DiCenzo RC. Effects of metronidazole on hepatic CYP3A4 activity. Pharmacotherapy 2001; 21:1192-5.

Haas DW, Bartlett JA, Andersen JW et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 2006; 43:783-6.

Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-400.

Haas DW, Smeaton LM, Shafer RW et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis 2005; 192:1931-42.

Haas J, Beer AG, Widschwendter P et al. LRP1b shows restricted expression in human tissues and binds to several extracellular ligands, including fibrinogen and apoE – carrying lipoproteins. Atherosclerosis 2011; 216:342-7.

Haas JP, Metzler M, Frank C, Haefner R, Wassmuth R. HLA-DQA1 gene expression profiling in oligoarticular JIA. Autoimmunity 2009; 42:389-91.

Haas S, Merkelbach-Bruse S, Justenhoven C, Brauch H, Fischer HP. Expression of xenobiotic and steroid hormone metabolizing enzymes in hepatocellular tumors of the non-cirrhotic liver. Pathol Res Pract 2009; 205:716-25.

Haas S, Pierl C, Harth V et al. Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas. Int J Cancer 2006; 119:1785-91.

Haass C, de Strooper B. The presenilins in Alzheimer’s disease-Proteolysis holds the key. Science 1999; 286:916-9.

Haaz MC, Riché C, Rivory LP, Robert J. Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes. Drug Metab Dispos 1998; 26:769-74.

Habbe N, Shi G, Meguid RA et al. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci USA 2008; 105:18913-8.

Habegger de Sorrentino A, López R, Motta P et al. HLA class II involvement in HIV-associated Toxoplasmic encephalitis development. Clin Immunol 2005; 115:133-7.

Haberl M, Anwald B, Klein K et al. Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet Genomics 2005; 15:609-24.

Habibollahi P, Ghahremani MH, Azizi E, Ostad SN. Multi drug resistance-1 (MDR1) expression in response to chronic diazinon exposure: an in vitro study on Caco-2 cells. Bull Environ Contam Toxicol 2011; 86:105-9.

Habtewold A, Amogne W, Makonnen E et al. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother 2011; 66:2350-61.

Hackam A, Yassa A, Singajara R et al. Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain. J Biol Chem 2000; 275:41299-308.

Hacker BM, Tomlinson JE, Wayman GA et al. Cloning, chromosomal mapping, and regulatory properties of the human type 9 adenylyl cyclase (ADCY9). Genomics 1998; 50:97-104.

Hackshaw A, Roughton M, Forsyth S et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol 2011; 29:1657-63.

Haddad A, Davis M, Lagman R. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer 2007; 15:251-7.

Hadidi H, Zahlsen K, Idle JR, Cholerton S. A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem Toxicol 1997; 35:903-7.

Hadjadj S, Fumeron F, Roussel R et al. Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies. Diabetes Care 2008; 31:1847-52.

Haduch A, Wójcikowski J, Daniel WA. The effect of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and newer antidepressant drugs on the activity and level of rat CYP3A. Eur Neuropsychopharmacol 2006; 16:178-86.

Ha-Duong NT, Dijols S, Macherey AC, Goldstein JA, Dansette PM, Mansuy D. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 2001; 40:12112-22.

Ha-Duong NT, Dijols S, Marques-Soares C, Minoletti C, Dansette PM, Mansuy D. Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily. J Med Chem 2001; 44:3622-31.

Haefeli WE, Bargetzi MJ, Follath F, Meyer UA. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol 1990; 15:776-9.

Haehner BD, Gorski JC, Vandenbranden M et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 1996; 50:52-9.

Haehner T, Refaie MO, Müller-Enoch D. Drug-drug interactions evaluated by a highly active reconstituted native human cytochrome P4503A4 and human NADPH-cytochrome P450 reductase system. Arzneimittelforschung 2004; 54:78-83.

Haenisch S, Laechelt S, Bruckmueller H et al. Down-regulation of ABCC2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. Mol Pharmacol 2011; 80:314-20.

Haerian BS, Lim KS, Mohamed EH et al. Lack of association of ABCB1 and PXR polymorphisms with response to treatment in epilepsy. Seizure 2011; 20:387-94.

Haerian BS, Lim KS, Mohamed EH et al. Lack of association of ABCB1 haplotypes on five loci with response to treatment in epilepsy. Seizure 2011; 20:546-53.

Haerian BS, Lim KS, Tan CT, Raymond AA, Mohamed Z. Association of ABCB1 gene polymorphisms and their haplotypes with response to antiepileptic drugs: a systematic review and meta-analysis. Pharmacogenomics 2011; 12:713-25.

Haerian BS, Lim KS, Tan HJ et al. Association between ABCB1 polymorphism and response to sodium valproate treatment in Malaysian epilepsy patients. Epileptic Disord 2011; 13:65-75.

Haerian BS, Roslan H, Raymond AA et al. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis. Seizure 2010; 19:339-46.

Hafez D, Huang JY, Huynh AM et al. Neprilysin-2 is an important β-amyloid degrading enzyme. Am J Pathol 2011; 178:306-12.

Haffen E, Vandel P, Broly F et al. Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype. Pharmacopsychiatry 1999; 32:232-4.

Hafner C, López-Knowles E, Luis NM et al. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci USA 2007; 104:13450-4.

Hafner V, Albermann N, Haefeli WE, Ebinger F. Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis. Antimicrob Agents Chemother 2008; 52:4172-4.

Hagaman JR, Moyer JS, Bachman ES et al. Angiotensin-converting enzyme and male fertility. Proc Nat Acad Sci USA 1998; 95:2552-7.

Hagelberg NM, Nieminen TH, Saari TI et al. Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol 2009; 65:263-71.

Hagen N, Olsen AK, Andersen JV, Tjørnelund J, Hansen SH. Characterization of mixtures of recombinant human cytochrome p450s as a screening model for metabolic stability in drug discovery. Xenobiotica 2002; 32:749-59.

Hagenah J, Saunders-Pullman R, Hedrich K et al. High mutation rate in dopa-responsive dystonia: detection with comprehensive GCHI screening. Neurology 2005; 64:908-11.

Hagenbuch N, Reichel C, Stieger B et al. Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver. J Hepatol 2001; 34:881-7.

Hager A, Bildau J, Kreuder J, Kaemmerer H, Hess J. Impact of genomic polymorphism on arterial hypertension after aortic coarctation repair. Int J Cardiol 2011; 151:63-8.

Hagerman RJ, Leehey M, Heinrichs W et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001; 57:127-30.

Hägg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 2001; 51:169-73.

Hägg S, Spigset O, Lakso HA, Dahlqvist R. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol 2001; 57:493-7.

Hägg S, Spigset O, Mjörndal T, Granberg K, Persbo-Lundqvist G, Dahlqvist R. Absence of interaction between erythromycin and a single dose of clozapine. Eur J Clin Pharmacol 1999; 55:221-6.

Hagihara K, Kazui M, Kurihara A et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 2009; 37:2145-52.

Hagihara K, Kazui M, Kurihara A et al. Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite. Drug Metab Dispos 2010; 38:898-904.

Hagmann W, Jesnowski R, Faissner R, Guo C, Löhr JM. ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology 2009; 9:136-44.

Hahm S, Mizuno TM, Wu TJ et al. Targeted deletion of the Vgf gene indicates that the encoded secretory peptide precursor plays a novel role in the regulation of energy balance. Neuron 1999; 23:537-48.

Hahn NM, Marsh S, Fisher W et al. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res 2006; 12:6094-9.

Hahn WH, Cho BS, Kim SD, Kim SK, Kang S. Interleukin-1 cluster gene polymorphisms in childhood IgA nephropathy. Pediatr Nephrol 2009; 24:1329-36.

Hahner S, Stürmer A, Fassnacht M et al. Etomidate unmasks intraadrenal regulation of steroidogenesis and proliferation in adrenal cortical cell lines. Horm Metab Res 2010; 42:528-34.

Hahnova-Cygalova L, Ceckova M, Staud F. Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy. Drug Metab Rev 2011; 43:53-68.

Hahntow IN, Schneller F, Oelsner M et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004; 18:747-55.

Haile CN, Kosten TA, Kosten TR. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse 2008; 34:355-81.

Haile CN, Kosten TR, Kosten TA. Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse 2009; 35:161-77.

Haiman CA, Stram DO, Pike MC et al. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet 2003; 12:2679-92.

Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996; 333:447-58.

Hajda J, Rentsch KM, Gubler C, Steinert H, Stieger B, Fattinger K. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur J Pharm Sci 2010; 41:729-35.

Hajeer AH, Sawidan FA, Bohlega S et al. HLA class I and class II polymorphisms in Saudi patients with myasthenia gravis. Int J Immunogenet 2009; 36:169-72

Hakk H, Diliberto JJ, Birnbaum LS. The effect of dose on 2,3,7,8-TCDD tissue distribution, metabolism and elimination in CYP1A2 (-/-) knockout and C57BL/6N parental strains of mice. Toxicol Appl Pharmacol 2009; 241:119-26.

Hakki T, Hübel K, Waldmann H, Bernhardt R. The development of a whole-cell based medium throughput screening system for the discovery of human aldosterone synthase (CYP11B2) inhibitors: old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and hypertension. J Steroid Biochem Mol Biol 2011; 125:120-8.

Hakkola J, Pelkonen O, Pasanen M, Raunio H. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. Crit Rev Toxicol 1998; 28:35-72.

Hakkola J, Raunio H, Purkunen R et al. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem Pharmacol 1996; 52:379-83.

Hakkola J, Raunio H, Purkunen R et al. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol Neonate 2001; 80:193-201.

Hakkola J, Tanaka E, Pelkonen O. Developmental expression of cytochrome P450 enzymes in human liver. Pharmacol Toxicol 1998; 82:209-17.

Hakonarson H, Qu HQ, Bradfield JP et al. A novel susceptibility locus for type 1 diabetes on Chr12q13 identified by a genome-wide association study. Diabetes 2008; 57:1143-6.

Hakonen AH, Davidzon G, Salemi R et al. Abundance of the POLG disease mutations in Europe, Australia, New Zealand, and the United States explained by single ancient European founders. Eur J Hum Genet 2007; 15:779-83.

Hakonen AH, Heiskanen S, Juvonen V et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet 2005; 77:430-41.

Håkonsen GD, Pettersen MH, Skurtveit S, Giverhaug T. Concomitant use of warfarin, analgesics and anti-inflammatory agents. Tidsskr Nor Laegeforen 2009; 129:1217-20.

Hakooz NM. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities. Curr Drug Metab 2009; 10:329-38.

Halberg RB, Katzung DS, Hoff PD et al. Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Proc Natl Acad Sci USA 2000; 97:3461-6.

Haldén AN, Arnoldsson K, Haglund P et al. Retention and maternal transfer of brominated dioxins in zebrafish (Danio rerio) and effects on reproduction, aryl hydrocarbon receptor-regulated genes, and ethoxyresorufin-O-deethylase (EROD) activity. Aquat Toxicol 2011; 102:150-61.

Halevi S, Yassin L, Eshel M et al. Conservation within the RIC-3 gene family. Effectors of mammalian nicotinic acetylcholine receptor expression. J Biol Chem 2003; 278:34411-7.

Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis 2009; 4:22.

Halperin F, Dluhy RG. Glucocorticoid-remediable aldosteronism. Endocrinol Metab Clin North Am 2011; 40:333-41, viii.

Halpert JR. Structure and function of cytochromes P450 2B: from mechanism-based inactivators to X-ray crystal structures and back. Drug Metab Dispos 2011; 39:1113-21.

Hals PA, Hall H, Dahl SG. Phenothiazine drug metabolites: dopamine D2 receptor, alpha 1- and alpha 2-adrenoceptor binding. Eur J Pharmacol 1986; 125:373-81.

Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003; 73:122-30.

Haluzík MM, Anderlová K, Dolezalová R et al. Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment. Physiol Res 2009; 58:93-9.

Haluzova I, Modra H, Blahova J, Marsalek P, Siroka Z, Groch L, Svobodova Z. Effects of subchronic exposure to Spartakus (prochloraz) on common carp Cyprinus carpio. Neuro Endocrinol Lett 2010; 31 Suppl 2:105-13.

Hall A, Elliott RL, Giblin GM et al. Piperidine-derived gamma-secretase modulators. Bioorg Med Chem Lett 2010; 20:1306-11.

Hall IP. Pharmacogenetics of asthma. Chest 2006; 130:1873-8.

Hall IP, Blakey JD, Al Balushi KA et al. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet 2006; 368:771-9.

Hall M, Persiani S, Cheung YL et al. Interaction of dexloxiglumide, a cholecystokinin type-1 receptor antagonist, with human cytochromes P450. Biopharm Drug Dispos 2004; 25:163-76.

Hall MJ, Liberman E, Dulkart O et al. Risk of colorectal neoplasia associated with the adenomatous polyposis coli E1317Q variant. Ann Oncol 2009; 20:1517-21.

Hallam PJ, Mannucci P, Tripodi A et al. Three novel PROC gene lesions causing protein C deficiency. Clin Genet 1998; 54:231-3.

Hallberg P, Karlsson J, Kurland L et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 2002; 20:2089-93.

Hallberg P, Karlsson J, Lind L et al. Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment-results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Clin Cardiol 2004; 27:287-90.

Hallberg P, Lind L, Michaëlsson K et al. Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy. BMC Cardiovasc Disord 2003; 3:11.

Halliday RC, Jones BC, Smith DA, Kitteringham NR, Park BK. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol 1995; 40:369-78.

Hallifax D, Galetin A, Houston JB. Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines. Xenobiotica 2008; 38:353-67.

Hallifax D, Rawden HC, Hakooz N, Houston JB. Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines. Drug Metab Dispos 2005; 33:1852-8.

Hallinan R, Crettol S, Agho K et al. Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study. Eur J Clin Pharmacol 2009; 65:1113-20.

Halling J, Petersen MS, Damkier P et al. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol 2005; 61:491-7.

Halling J, Petersen MS, Grandjean P, Weihe P, Brosen K. Genetic predisposition to Parkinson’s disease: CYP2D6 and HFE in the Faroe Islands. Pharmacogenet Genomics 2008; 18:209-12.

Halling J, Weihe P, Brosen K. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients. Ther Drug Monit 2008; 30:271-5.

Halling J, Weihe P, Brosen K. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. Br J Clin Pharmacol 2008; 65:134-8.

Hallström H, Melhus H, Glynn A, Lind L, Syvänen AC, Michaëlsson K. Coffee consumption and CYP1A2 genotype in relation to bone mineral density of the proximal femur in elderly men and women: a cohort study. Nutr Metab 2010; 7:12.

Ham BJ, Lee BC, Paik JW et al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:104-7.

Hamada N, Miyata M, Eto H et al. Loss of clusterin limits atherosclerosis in apolipoprotein E-deficient mice via reduced expression of Egr-1 and TNF-α. J Atheroscler Thromb 2011; 18:209-16.

Hamada S, Satoh K, Hirota M et al. The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2. J Cell Physiol 2011. doi:10. 1002/jcp. 22781.

Hamaguchi T, Okino S, Sodeyama N et al. Association of a polymorphism of the transforming growth factor-beta1 gene with cerebral amyloid angiopathy. J Neurol Neurosurg Psychiatry 2005; 76:696-9.

Hamajima N, Kouwaki M, Vreken P et al. Dihydropyrimidinase deficiency: structural organization, chromosomal localization, and mutation analysis of the human dihydropyrimidinase gene. Am J Hum Genet 1998; 63:717-26.

Hamajima N, Matsuo K, Saito T et al. Interleukin 1 polymorphisms, lifestyle factors, and Helicobacter pylori infection. Jpn J Cancer Res 2001; 92:383-9.

Hamajima N, Naito M, Kondo T, Goto Y. Genetic factors involved in the development of Helicobacter pylori-related gastric cancer. Cancer Sci 2006; 97:1129-38.

Hamajima N, Okada R, Kawai S et al. Significant association of serum uric acid levels with SLC2A9 rs11722228 among a Japanese population. Mol Genet Metab 2011; 103:378-82.

Hamaoka N, Oda Y, Hase I et al. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. Clin Pharmacol Ther 1999; 66:110-7.

Hamaoka N, Oda Y, Hase I, Asada A. Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies. Br J Anaesth 2001; 86:540-4.

Hamberg AK, Dahl ML, Barban M et al. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther 2007; 81:529-38.

Hamdani N, Tabeze JP, Ramoz N et al. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. Eur Neuropsychopharmacol 2008; 18:34-40.

Hamdi HK, Reznik J, Castellon R et al. Alu DNA polymorphism in ACE gene is protective for age-related macular degeneration. Biochem Biophys Res Commun 2002; 295:668-72.

Hamdy SM, Bakeer HM, Eskande EF, Sayed ON. Effect of acrylamide on some hormones and endocrine tissues in male rats. Hum Exp Toxicol 2011. doi:10. 1177/0960327111417267.

Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos 1998; 26:536-9.

Hamelin BA, Turgeon J, Vallée F, Bélanger PM, Paquet F, LeBel M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996; 60:512-21.

Hamid KA, Lin Y, Gao Y, Katsumi H, Sakane T, Yamamoto A. The effect of wellsolve, a novel solubilizing agent, on the intestinal barrier function and intestinal absorption of griseofulvin in rats. Biol Pharm Bull 2009; 32:1898-905.

Hamid YH, Urhammer SA, Jensen DP et al. Variation in the interleukin-6 receptor gene associates with type 2 diabetes in Danish whites. Diabetes 2004; 53:3342-5.

Hamidi Asl K, Liepnieks JJ, Nakamura M, Parker F, Benson MD. A novel apolipoprotein A-1 variant, Arg173 to pro, associated with cardiac and cutaneous amyloidosis. Biochem Biophys Res Commun 1999; 257:584-8.

Hamidovic A, Dlugos A, Palmer AA, de Wit H. Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers. Behav Genet 2010; 40:255-61.

Hamidovic A, Hahn K, Kolesar J. Clinical significance of ABCB1 genotyping in oncology. J Oncol Pharm Pract 2010; 16:39-44.

Hamilton GA, Jolley SL, Gilbert D, Coon DJ, Barros S, LeCluyse EL. Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions. Cell Tissue Res 2001; 306:85-99.

Hamilton HB, Neel JV. Genetic heterogeneity in human acatalasia. Am J Hum Genet 1963; 15:408-19.

Hamilton JW. Gentamicin in pharmacogenetic approach to treatment of cystic fibrosis. Lancet 2001; 358:2014-6.

Hamilton SP, Slager SL, de Leon AB et al. Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacology 2004; 29:558-65.

Hamilton SR, Liu B, Parsons RE et al. The molecular basis of Turcot’s syndrome. N Engl J Med 1995; 332:839-47.

Hamitouche S, Poupon J, Dreano Y, Amet Y, Lucas D. Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: role of CYP2C isoforms in human liver microsomes. Toxicol Lett 2006; 167:221-30.

Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001; 69:114-21.

Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 1997; 54:33-41.

Hammann F, Gutmann H, Baumann U, Helma C, Drewe J. Classification of cytochrome p(450) activities using machine learning methods. Mol Pharm 2009; 6:1920-6.

Hammer C, Kapeller J, Endele M et al. Functional variants of the serotonin receptor type 3A and B gene are associated with eating disorders. Pharmacogenet Genomics 2009; 19:790-9.

Hamming KS, Soliman D, Matemisz LC et al. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes 2009; 58:2419-24.

Hammoud AO, Griffin J, Meikle AW, Gibson M, Peterson CM, Carrell DT. Association of aromatase (TTTAn) repeat polymorphism length and the relationship between obesity and decreased sperm concentration. Hum Reprod 2010; 25:3146-51.

Hamouchene H, Arlt VM, Giddings I, Phillips DH. Influence of cell cycle on responses of MCF-7 cells to benzo[a]pyrene. BMC Genomics 2011; 12:333.

Hampras SS, Sucheston L, Weiss J et al. Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia. Int J Mol Epidemiol Genet 2010; 1:201-7.

Hamrefors V, Orho-Melander M, Krauss RM et al. A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women. J Lipid Res 2010; 51:625-34.

Hamzeiy H, Bombail V, Plant N, Gibson G, Goldfarb P. Transcriptional regulation of cytochrome P4503A4 gene expression: effects of inherited mutations in the 5’-flanking region. Xenobiotica 2003; 33:1085-95.

Hamzeiy H, Vahdati-Mashhadian N, Edwards HJ, Goldfarb PS. Mutation analysis of the human CYP3A4 gene 5’ regulatory region: population screening using non-radioactive SSCP. Mutat Res 2002; 500:103-10.

Han B, Gao G, Wu W et al. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer 2011; 72:238-43.

Han B, Zhang JT. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. Curr Med Chem Anticancer Agents 2004; 4:31-42.

Han EH, Hwang YP, Kim HG et al. CCAAT/enhancer-binding protein β activation by capsaicin contributes to the regulation of CYP1A1 expression, mediated by the aryl hydrocarbon receptor. Br J Pharmacol 2011. doi:10. 1111/j. 1476-5381. 2011. 01232. x.

Han EH, Kim HG, Hwang YP, Song GY, Jeong HG. Prostaglandin E2 induces CYP1B1 expression via ligand-independent activation of the ERalpha pathway in human breast cancer cells. Toxicol Sci 2010; 114:204-16.

Han J, Colditz GA, Liu JS, Hunter DJ. Genetic variation in XPD, sun exposure, and risk of skin cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:1539-44.

Han JI, Son HW, Park SC, Na KJ. Novel insertion mutation of ABCB1 gene in an ivermectin-sensitive Border Collie. J Vet Sci 2010; 11:341-4.

Han JY, Lim HS, Park YH, Lee SY, Lee JS. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 2009; 63:115-20.

Han JY, Lim HS, Yoo YK et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007; 110:138-47.

Han KH, Iijuka M, Shimada K et al. Adzuki resistant starch lowered serum cholesterol and hepatic 3-hydroxy-3-methylglutaryl-CoA mRNA levels and increased hepatic LDL-receptor and cholesterol 7alpha-hydroxylase mRNA levels in rats fed a cholesterol diet. Br J Nutr 2005; 94:902-8.

Han MR, Schellenberg GD, Wang LS; Alzheimer’s Disease Neuroimaging Initiative. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study. BMC Neurol 2010; 10:90.

Han N, Yan Z, Guo CA et al. Effects of p-glycoprotein on steroid-induced osteonecrosis of the femoral head. Calcif Tissue Int 2010; 87:246-53.

Han RQ, Ouyang YB, Xu L, Agrawal R, Patterson AJ, Giffard RG. Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg 2009; 108:280-7.

Han S, Chiang JY. Mechanism of vitamin D receptor inhibition of cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes. Drug Metab Dispos 2009; 37:469-78.

Han S, Choi K, Kim J et al. Endocrine disruption and consequences of chronic exposure to ibuprofen in Japanese medaka (Oryzias latipes) and freshwater cladocerans Daphnia magna and Moina macrocopa. Aquat Toxicol 2010; 98:256-64.

Han S, Li T, Ellis E, Strom S, Chiang JY. A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Mol Endocrinol 2010; 24:1151-64.

Han SH, Chung MJ, Lee SJ, Rhee C. Digestion-resistant fraction from soybean [Glycine max (L. ) Merrill] induces hepatic LDL receptor and CYP7A1 expression in apolipoprotein E-deficient mice. J Nutr Biochem 2006; 17:682-8.

Han SW, Oh DY, Im SA et al. Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6. Cancer Sci 2010; 101:793-9.

Han X, Kitamoto S, Wang H, Boisvert WA. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J 2010; 24:2869-80.

Han X, Zheng T, Foss FM et al. Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. Am J Hematol 2010; 85:51-6.

Han Y, Gu S, Oota H et al. Evidence of positive selection on a class I ADH locus. Am J Hum Genet 2007; 80:441-56.

Han YH, Busler D, Hong Y, Tian Y, Chen C, Rodrigues AD. Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters. Drug Metab Dispos 2010; 38:1072-82.

Han YL, Yu HL, Li D et al. In vitro inhibition of Huanglian [Rhizoma coptidis (L. )] and its six active alkaloids on six cytochrome P450 isoforms in human liver microsomes. Phytother Res 2011; 25:1660-5.

Han ZX, Yang L, Zhang L, Xu C, Shu WQ. The antagonistic action of epigallocatechin-3-gallate on microcystin LR-induced oxidative damage on hepatocytes of mice and the expression of cytochrome P450 2E1. Zhonghua Yu Fang Yi Xue Za Zhi 2010; 44:24-9.

Hanafi-Bojd MY, Iranshahi M, Mosaffa F, Tehrani SO, Kalalinia F, Behravan J. Farnesiferol A from Ferula persica and Galbanic Acid from Ferula szowitsiana inhibit P-glycoprotein-mediated Rhodamine efflux in breast cancer cell lines. Planta Med 2011; 77:1590-3.

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.

Hanatani T, Fukuda T, Ikeda M et al. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro. Pharmacogenomics J 2001; 1:288-92.

Hancox RJ. Interactions between corticosteroids and beta2-agonists. Clin Rev Allergy Immunol 2006; 31:231-46.

Handolias D, Hamilton AL, Salemi R et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 2010; 102:1219-23.

Handschin C, Podvinec M, Amherd R, Looser R, Ourlin JC, Meyer UA. Cholesterol and bile acids regulate xenosensor signaling in drug-mediated induction of cytochromes P450. J Biol Chem 2002; 277:29561-7.

Hani EH, Suaud L, Boutin P et al. A missense mutation in hepatocyte nuclear factor-4 alpha, resulting in a reduced transactivation activity, in human late-onset non-insulin-dependent diabetes mellitus. J Clin Invest 1998; 101:521-6.

Hanioka N, Kimura S, Meyer UA, Gonzalez FJ. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934-A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3’ splice recognition site. Am J Hum Genet 1990; 47:994-1001.

Hanioka N, Matsumoto K, Saito Y, Narimatsu S. Functional characterization of CYP2C8. 13 and CYP2C8. 14: catalytic activities toward paclitaxel. Basic Clin Pharmacol Toxicol 2010; 107:565-9.

Hanioka N, Naito T, Narimatsu S. Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation. Chemosphere 2008; 74:33-6.

Hanioka N, Oka H, Nagaoka K, Ikushiro S, Narimatsu S. Effect of UDP-glucuronosyltransferase 2B15 polymorphism on bisphenol A glucuronidation. Arch Toxicol 2011. doi:10. 1007/s00204-011-0690-5.

Hanioka N, Okumura Y, Saito Y et al. Catalytic roles of CYP2D6. 10 and CYP2D6. 36 enzymes in mexiletine metabolism: in vitro functional analysis of recombinant proteins expressed in Saccharomyces cerevisiae. Biochem Pharmacol 2006; 71:1386-95.

Hanioka N, Ozawa S, Jinno H et al. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab Dispos 2002; 30:391-6.

Hanioka N, Yamamoto M, Tanaka-Kagawa T, Jinno H, Narimatsu S. Functional characterization of human cytochrome P4502E1 allelic variants: in vitro metabolism of benzene and toluene by recombinant enzymes expressed in yeast cells. Arch Toxicol 2010; 84:363-71.

Haniu M, Denis P, Young Y et al. Characterization of Alzheimer’s beta-secretase protein BACE. A pepsin family member with unusual properties. J Biol Chem 2000; 275:21099-106.

Hanke U, May K, Rozehnal V, Nagel S, Siegmund W, Weitschies W. Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2). Eur J Pharm Biopharm 2010; 76:260-8.

Hankinson O. Role of coactivators in transcriptional activation by the aryl hydrocarbon receptor. Arch Biochem Biophys 2005; 433:379-86.

Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 1995; 35:307-40.

Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 2011; 7:267-86.

Hanlon N, Coldham N, Sauer MJ, Ioannides C. Up-regulation of the CYP1 family in rat and human liver by the aliphatic isothiocyanates erucin and sulforaphane. Toxicology 2008; 252:92-8.

Hanlon N, Konsue N, Coldham N, Sauer MJ, Ioannides C. Exposure to isothiocyanates suppresses urinary mutagenicity in rats treated with heterocyclic amine IQ: lack of association with CYP1 activity. Nutr Cancer 2011; 63:300-5.

Hannila-Handelberg T, Kontula KK, Paukku K et al. Common genetic variations of the renin-angiotensin-aldosterone system and response to acute angiotensin I-converting enzyme inhibition in essential hypertension. J Hypertens 2010; 28:771-9.

Hänninen K, Katila H, Kampman O et al. Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia. Neurosci Lett 2006; 407:195-8.

Hansen AM, Christensen IT, Hansen JB, Carr RD, Ashcroft FM, Wahl P. Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes 2002; 51:2789-95.

Hansen L, Ekstrom CT, Palacios RT. The Pro12-to-Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocr Metab 2006; 91:3446-50.

Hansen L, Ekstrøm CT, Tabanera Y Palacios R, Anant M, Wassermann K, Reinhardt RR. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 2006; 91:3446-50.

Hansen SK, Rose CS, Glümer C et al. Variation near the hepatocyte nuclear factor (HNF)-4alpha gene associates with type 2 diabetes in the Danish population. Diabetologia 2005; 48:452-8.

Hansen T, Borlak J, Bader A. Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica 2000; 30:27-46.

Hansen T, Echwald SM, Hansen L et al. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 1998; 47:598-605.

Hansen T, Hemmingsen RP, Wang AG et al. Apolipoprotein D is associated with long-term outcome in patients with schizophrenia. Pharmacogenomics J 2006; 6:120-5.

Hansen TS, Nilsen OG. In vitro CYP3A4 metabolism: inhibition by Echinacea purpurea and choice of substrate for the evaluation of herbal inhibition. Basic Clin Pharmacol Toxicol 2008; 103:445-9.

Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001; 154:193-206.

Hanson KL, Vandenbrink BM, Babu KN, Allen KE, Nelson WL, Kunze KL. Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: Opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (S)-Fluoxetine and N-desmethyldiltiazem. Drug Metab Dispos 2010; 38:963-72.

Hansson JH, Schild L, Lu Y et al. A de novo missense mutation of the beta subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc Natl Acad Sci USA 1995; 92:11495-9.

Hansson M, Olin M, Floren CH et al. Unique patient with cerebrotendinous xanthomatosis. Evidence for presence of a defect in a gene that is not identical to sterol 27-hydroxylase. J Intern Med 2007; 261:504-10.

Hansson O, Peterson A, Leist M, Nicotera P, Castilho R, Brundin P. Transgenic mice expressing a Huntington’s disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Nat Acad Sci USA 1999; 96:8727-32.

Hao B, Chen ZW, Zhou XJ et al. Identification of phase-I metabolites and chronic toxicity study of the Kv1. 3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat. Xenobiotica 2011; 41:198-211.

Hao C, Liu W, Luan X et al. Aquaporin-4 knockout enhances astrocyte toxicity induced by 1-methyl-4-phenylpyridinium ion and lipopolysaccharide via increasing the expression of cytochrome P4502E1. Toxicol Lett 2010; 198:225-31.

Hao CF, Zhang N, Qu Q, Wang X, Gu HF, Chen ZJ. Evaluation of the association between the CYP19 Tetranucleotide (TTTA)n polymorphism and polycystic ovarian syndrome(PCOS) in Han Chinese women. Neuro Endocrinol Lett 2010; 31:370-4.

Hao J, Chen H, Madigan MC et al. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer 2010; 103:1008-18.

Hao JQ, Chen Y, Li SM et al. Relationship between the polymorphisms of UGT1A6 genes and anti-tuberculosis drug induced hepatic-injury. Zhonghua Gan Zang Bing Za Zhi 2011; 19:201-4.

Hao K, Peng S, Xing H et al. beta(3) Adrenergic receptor polymorphism and obesity-related phenotypes in hypertensive patients. Obes Res 2004; 12:125-30.

Hao M, Ba Q, Yin J, Li J, Zhao Y, Wang H. Deglycosylated ginsenosides are more potent inducers of CYP1A1, CYP1A2 and CYP3A4 expression in HepG2 cells than glycosylated ginsenosides. Drug Metab Pharmacokinet 2011; 26:201-5.

Hao M, Zhao Y, Chen P et al. Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS One 2008. doi:10. 1371/journal. pone. 0002697.

Hao Q, Su H, Marchuk DA et al. Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation. Am J Physiol Heart Circ Physiol 2008; 295:2250-6.

Hao Q, Wenfang C, Xia A et al. Effects of a moderate-intensity static magnetic field and adriamycin on K562 cells. Bioelectromagnetics 2011; 32:191-9.

Haouala A, Rumpold H, Untergasser G et al. siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors. Drug Metab Lett 2010; 4:114-9.

Haque W, Garg A, Agarwal AK. Enzymatic activity of naturally occurring 1-acylglycerol-3-phosphate-O-acyltransferase 2 mutants associated with congenital generalized lipodystrophy. Biochem Biophys Res Commun 2005; 327:446-53.

Hara H, Mitani N, Adachi T. Inhibitory effect of nitric oxide on the induction of cytochrome P450 3A4 mRNA by 1,25-dihydroxyvitamin D3 in Caco-2 cells. Free Radic Res 2000; 33:279-85.

Hara H, Yasunami Y, Adachi T. Alteration of cellular phosphorylation state affects vitamin D receptor-mediated CYP3A4 mRNA induction in Caco-2 cells. Biochem Biophys Res Commun 2002; 296:182-8.

Hara H, Yasunami Y, Adachi T. Loss of CYP3A7 gene induction by 1,25-dihydroxyvitamin D3 is caused by less binding of VDR to the proximal ER6 in CYP3A7 gene. Biochem Biophys Res Commun 2004; 321:909-15.

Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann DA. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab 2002; 87:772-5.

Hara Y, Nakajima M, Miyamoto KI, Yokoi T. Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: prediction of in vivo drug interactions. Xenobiotica 2005; 35:549-60.

Harada A, Oguchi K, Okabe S et al. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 1994; 369:488-91.

Harada LM, Carrilho AJ, Oliveira HC, Nakandakare ER, Quintão EC. Regulation of hepatic cholesterol metabolism in CETP/LDLr mice by cholesterol feeding and by drugs (cholestyramine and lovastatin) that lower plasma cholesterol. Clin Exp Pharmacol Physiol 2006; 33:1209-15.

Harada S. Classification of alcohol metabolizing enzymes and polymorphisms-specificity in Japanese. Nihon Arukoru Yakubutsu Igakkai Zasshi 2001; 36:85-106.

Haraguchi S, Ho SK, Morrow M, Goodenow MM, Sleasman JW. Developmental regulation of P-glycoprotein activity within thymocytes results in increased protease inhibitor activity. J Leukoc Biol 2011; 90:653-60.

Harbottle A, Daly AK, Atherton K, Campbell FC. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int J Cancer 2001; 92:777-83.

Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP. Melatonergic drugs in clinical practice. Arzneimittelforschung 2008; 58:1-10.

Harden CL, Leppik I. Optimizing therapy of seizures in women who use oral contraceptives. Neurology 2006; 67(12 Suppl 4):56-8.

Hardie RA, Luo M, Bruneau B et al. Human leukocyte antigen-DQ alleles and haplotypes and their associations with resistance and susceptibility to HIV-1 infection. AIDS 2008; 22:807-16.

Hardwick JP. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem Pharmacol 2008; 75:2263-75.

Hardy DO, Scher HI, Bogenreider T et al. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 1996; 81:4400-5.

Hardy J, Crook R, Perry R, Raghavan R, Roberts G. ApoE genotype and Down’s syndrome. Lancet 1994; 343:979-80.

Hardy J, Israël A. In search of g-secretase. Nature 1999; 398:466-7.

Hargrove JL, Greenspan P, Hartle DK, Dowd C. Inhibition of aromatase and α-amylase by flavonoids and proanthocyanidins from Sorghum bicolor bran extracts. J Med Food 2011; 14:799-807.

Hariparsad N, Carr BA, Evers R, Chu X. Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 2008; 36:1046-55.

Hariparsad N, Chu X, Yabut J et al. Identification of pregnane-X receptor target genes and coactivator and corepressor binding to promoter elements in human hepatocytes. Nucleic Acids Res 2009; 37:1160-73.

Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004; 44:1273-81.

Harisa Gel-D, Ibrahim MF, Alanazi FK. Characterization of human erythrocytes as potential carrier for pravastatin: an in vitro study. Int J Med Sci 2011; 8:222-30.

Haritos VS, Ching MS, Ghabrial H et al. Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2. Pharmacogenetics 1998; 8:423-32.

Haritos VS, Ghabrial H, Ahokas JT, Ching MS. Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics 2000; 10:591-603.

Härkönen PL, Mäkelä SI. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol 2004; 92:297-305.

Harlow EG, Till SM, Russell TA, Wijetunge LS, Kind P, Contractor A. Critical period plasticity is disrupted in the barrel cortex of FMR1 knockout mice. Neuron 2010; 65:385-98.

Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med 2004; 10:481-3.

Harmon DL, Shields DC, Woodside JV et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 1999; 17:298-309.

Harmsen S, Koster AS, Beijnen JH, Schellens JH, Meijerman I. Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction. Drug Metab Dispos 2008; 36:1166-71.

Harmsen S, Meijerman I, Beijnen JH, Schellens JH. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat Rev 2007; 33:369-80.

Harmsen S, Meijerman I, Beijnen JH, Schellens JH. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol 2009; 64:35-43.

Harmsen S, Meijerman I, Febus CL, Maas-Bakker RF, Beijnen JH, Schellens JH. PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol 2010; 66:765-71.

Harmsze A, van Werkum JW, Bouman HJ et al. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics 2010; 20:18-25.

Harmsze AM, de Boer A, Boot H et al. Interaction between clopidogrel and proton pump inhibitors. Ned Tijdschr Geneeskd 2011; 155:2442.

Harmsze AM, Robijns K, van Werkum JW et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010; 103:920-5.

Harmsze AM, van Werkum JW, Moral F et al. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets 2011; 22:98-102.

Harmsze AM, van Werkum JW, Ten Berg JM et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J 2010; 31:3046-53.

Harold D, Macgregor S, Patterson CE et al. A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer’s disease. Pharmacogenet Genomics 2006; 16:75-7.

Harper J, Burns JL, Foulstone EJ, Pignatelli M, Zaina S, Hassan AB. Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting. Cancer Res 2006; 66:1940-8.

Harper JW, Elledge SJ. Cdk inhibitors in development and cancer. Curr Opin Genet Dev 1996; 6:56-64.

Harper P, Youngman S, Anderson M et al. Genetic linkage between Huntington’s disease and the DNA polymorphism G8 in South Wales families. J Med Genet 1985; 22:447-50.

Harpstrite SE, Prior JL, Sivapackiam J, Collins SD, Rath NP, Sharma V. Synthesis, characterization, and molecular structure of a novel zinc (II) complex: assessment of impact of MDR1Pgp expression on its cytotoxic activity. Med Chem 2010; 6:191-9.

Harrill AH, Watkins PB, Su S et al. Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res 2009; 19:1507-15.

Harrington C, Sawchak S, Chiang C et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: Two phase 3 studies. Curr Alzheimer Res 2011; 8:592-606.

Harrington CR, Roth M, Xuereb JH, McKenna PJ, Wischik CM. Apoliprotein E type 4 allele frequency is increased in patients with schizophrenia. Neurosci Lett 1995; 202:101-4.

Harrington DJ, Gorska R, Wheeler R et al. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost 2008; 6:1663-70.

Harris FM, Brecht WJ, Xu Q et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer’s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Nat Acad Sci USA 2003; 100:10966-71.

Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009; 17:55-67.

Harris RZ, Inglis AM, Miller AK et al. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics. J Clin Pharmacol 1999; 39:1189-94.

Harris RZ, Jang GR, Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet 2003; 42:1071-88.

Harris RZ, Salfi M, Posvar E, Hoelscher D, Padhi D. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol 2007; 63:159-63.

Harris RZ, Salfi M, Sullivan JT, Padhi D. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. Clin Pharmacokinet 2007; 46:495-501.

Harris RZ, Tsunoda SM, Mroczkowski P, Wong H, Benet LZ. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther 1996; 59:429-35.

Harris SR, Gedge JI, Nedderman AN, Roffey SJ, Savage M. A sensitive HPLC-MS-MS assay for quantitative determination of midazolam in dog plasma. J Pharm Biomed Anal 2004; 35:127-34.

Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Nat Acad Sci USA 2008; 105:1516-21.

Harrison CM, Pompilius M, Pinkerton KE, Ballinger SW. Mitochondrial oxidative stress significantly influences atherogenic risk and cytokine-induced oxidant production. Environ Health Perspect 2011; 119:676-81.

Harrison FE, May JM, McDonald MP. Vitamin C deficiency increases basal exploratory activity but decreases scopolamine-induced activity in APP/PSEN1 transgenic mice. Pharmacol Biochem Behav 2010; 94:543-52.

Harrison PJ, Lyon L, Sartorius LJ, Burnet PW, Lane TA. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol 2008; 22:308-22.

Harrison-Findik DD. Is the iron regulatory hormone hepcidin a risk factor for alcoholic liver disease? World J Gastroenterol 2009; 15:1186-93.

Hartford C, Vasquez E, Schwab M et al. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res 2007; 67:4965-72.

Harth V, Schafer M, Abel J et al. Head and neck squamous-cell cancer and its association with polymorphic enzymes of xenobiotic metabolism and repair. J Toxicol Environ Health A 2008; 71:887-97.

Hartiala J, Li D, Conti DV et al. Genetic contribution of the leukotriene pathway to coronary artery disease. Hum Genet 2011; 129:617-27.

Hartley DP, Dai X, Yabut J et al. Identification of potential pharmacological and toxicological targets differentiating structural analogs by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell lines. Pharmacogenet Genomics 2006; 16:579-99.

Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J Lipid Res 2009; 50:1090-100.

Hartman HB, Lai K, Evans MJ. Loss of small heterodimer partner expression in the liver protects against dyslipidemia. J Lipid Res 2009; 50:193-203.

Hartman JC, Brouwer K, Mandagere A, Melvin L, Gorczynski R. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol 2010; 88:682-91.

Hartsel SC, Weiland TR. Amphotericin B binds to amyloid fibrils and delays their formation: a therapeutic mechanism? Biochemistry 2003; 42:6228-33.

Härtter S, Grözinger M, Weigmann H, Röschke J, Hiemke C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther 2000; 67:1-6.

Härtter S, Tybring G, Friedberg T, Weigmann H, Hiemke C. The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res 2002; 19:1034-7.

Hartz AM, Madole EK, Miller DS, Bauer B. Estrogen receptor beta signaling through phosphatase and tensin homolog/phosphoinositide 3-kinase/Akt/glycogen synthase kinase 3 down-regulates blood-brain barrier breast cancer resistance protein. J Pharmacol Exp Ther 2010; 334:467-76.

Hartz AM, Mahringer A, Miller DS, Bauer B. 17-β-Estradiol: a powerful modulator of blood-brain barrier BCRP activity. J Cereb Blood Flow Metab 2010; 30:1742-55.

Hartz AM, Miller DS, Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer’s disease. Mol Pharmacol 2010; 77:715-23.

Harvey JL, Paine AJ, Maurel P, Wright MC. Effect of the adrenal 11-beta-hydroxylase inhibitor metyrapone on human hepatic cytochrome P-450 expression: induction of cytochrome P-450 3A4. Drug Metab Dispos 2000; 28:96-101.

Haschke-Becher E, Kirchheiner J, Trummer O et al. Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort. Pharmacogenomics 2010; 11:1359-65.

Hasegawa M, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. J Am Soc Nephrol 2007; 18:37-45.

Hasegawa Y, Kishimoto S, Shibatani N et al. The pharmacokinetics of morphine and its glucuronide conjugate in a rat model of streptozotocin-induced diabetes and the expression of MRP2, MRP3 and UGT2B1 in the liver. J Pharm Pharmacol 2010; 62:310-4.

Hasegawa Y, Kishimoto S, Takahashi H, Inotsume N, Takeuchi Y, Fukushima S. Altered expression of MRP2, MRP3 and UGT2B1 in the liver affects the disposition of morphine and its glucuronide conjugate in a rat model of cholestasis. J Pharm Pharmacol 2009; 61:1205-10.

Hashemi-Soteh SM, Sarzare F, Merat F, Salehifar E, Shiran MR. Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3, *4, and *6) within an Iranian population (Mazandaran). Genet Test Mol Biomarkers 2011. doi:10. 1089/gtmb. 2011. 0033.

Hashida T, Masuda S, Uemoto S, Saito H, Tanaka K, Inui K. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 2001; 69:308-16.

Hashikawa-Hobara N, Hashikawa N, Yutani C et al. The Akt-nitric oxide-cGMP pathway contributes to nerve growth factor-mediated neurite outgrowth in apolipoprotein E knockout mice. J Pharmacol Exp Ther 2011; 338:694-700.

Hashimoto H, Nakagawa T, Yokoi T, Sawada M, Itoh S, Kamataki T. Fetus-specific CYP3A7 and adult-specific CYP3A4 expressed in Chinese hamster CHL cells have similar capacity to activate carcinogenic mycotoxins. Cancer Res 1995; 55:787-91.

Hashimoto H, Toide K, Kitamura R et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 1993; 218:585-95.

Hashimoto K, Kataoka M, Tatsuta M et al. Benzimidazole-5-sulfonamides as novel nonpeptide luteinizing hormone releasing hormone (LHRH) antagonists: minimization of mechanism-based CYP3A4 inhibition. Chem Pharm Bull 2005; 53:1314-7.

Hashimoto R, Noguchi H, Hori H et al. Association between the dysbindin gene (DTNBP1) and cognitive functions in Japanese subjects. Psychiatry Clin Neurosci 2009; 63:550-6.

Hashizume T, Imaoka S, Mise M et al. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 2002; 300:298-304.

Hashizume T, Mise M, Matsumoto S et al. A novel cytochrome P450 enzyme responsible for the metabolism of ebastine in monkey small intestine. Drug Metab Dispos 2001; 29:798-805.

Hashizume T, Mise M, Terauchi Y et al. N-Dealkylation and hydroxylation of ebastine by human liver cytochrome P450. Drug Metab Dispos 1998; 26:566-71.

Hasin Y, Avidan N, Bercovich D et al. A paradigm for single nucleotide polymorphism analysis: the case of the acetylcholinesterase gene. Hum Mutat 2004; 24:408-16.

Hasin Y, Avidan N, Bercovich D et al. Analysis of genetic polymorphisms in acetylcholinesterase as reflected in different populations. Curr Alzheimer Res 2005; 2:207-18.

Haskó G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004; 25:33-9.

Haslemo T, Refsum H, Molden E. The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine. Br J Clin Pharmacol 2011; 71:611-5.

Hassan A, Burhenne J, Riedel KD et al. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit 2011; 33:86-93.

Hassan BA, Yusoff ZB. Genetic polymorphisms in the three malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy. Asian Pac J Cancer Prev 2011; 12:185-91.

Hassan HE, Myers AL, Lee IJ, Chen H, Coop A, Eddington ND. Regulation of gene expression in brain tissues of rats repeatedly treated by the highly abused opioid agonist, oxycodone: microarray profiling and gene mapping analysis. Drug Metab Dispos 2010; 38:157-67.

Hassan PC, Sproule BA, Naranjo CA, Herrmann N. Dose-response evaluation of the interaction between sertraline and alprazolam in vivo. J Clin Psychopharmacol 2000; 20:150-8.

Hasselstrøm J, Linnet K. Quetiapine serum concentrations in psychiatric patients: the influence of comedication. Ther Drug Monit 2004; 26:486-91.

Hasselstrøm J, Linnet K. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions. Drug Metabol Drug Interact 2006; 21:187-211.

Hasstedt SJ, Bovill EG, Callas PW, Long GL. An unknown genetic defect increases venous thrombosis risk, through interaction with protein C deficiency. Am J Hum Genet 1998; 63:569-76.

Hata A, Namikawa C, Sasaki M et al. Angiotensinogen as a risk factor for essential hypertension in Japan. J Clin Invest 1994; 93:1285-7.

Hata M, Tanaka Y, Kyoda N et al. An epoxidation mechanism of carbamazepine by CYP3A4. Bioorg Med Chem 2008; 16:5134-48.

Hata S, Miki Y, Fujishima F et al. Cytochrome 3A and 2E1 in human liver tissue: Individual variations among normal Japanese subjects. Life Sci 2010; 86:393-401.

Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter. Am J Physiol Gastrointest Liver Physiol 2011; 300:461-9.

Hatcher D, Daniels G, Osman I, Lee P. Molecular mechanisms involving prostate cancer racial disparity. Am J Transl Res 2009; 1:235-48.

Hatjiharissi E, Hansen M, Santos DD et al. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma 2007; 7:286-90.

Hatok J, Zubor P, Galo S et al. Endometrial aromatase mRNA as a possible screening tool for advanced endometriosis and adenomyosis. Gynecol Endocrinol 2011; 27:331-6.

Hatori A, Yui J, Yanamoto K et al. Determination of radioactivity in infant, juvenile and adult rat brains after injection of anti-influenza drug [(11)C]oseltamivir using PET and autoradiography. Neurosci Lett 2011; 495:187-91.

Hatorp V, Hansen KT, Thomsen MS. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 2003; 43:649-60.

Hattangady NG, Olala LO, Bollag WB, Rainey WE. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol 2011. doi:10. 1016/j. mce. 2011. 07. 034.

Hattori E, Nakajima M, Yamada K et al. Variable number of tandem repeat polymorphisms of DRD4: re-evaluation of selection hypothesis and analysis of association with schizophrenia. Eur J Hum Genet 2009; 17:793-801.

Haufroid V. Genetic polymorphisms of ATP-Binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. Curr Drug Targets 2011; 12:631-46.

Haughey NJ, Bandaru VV, Bae M, Mattson MP. Roles for dysfunctional sphingolipid metabolism in Alzheimer’s disease neuropathogenesis. Biochim Biophys Acta 2010; 1801:878-86.

Hauner H, Meier M, Jöckel KH, Frey UH, Siffert W. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics 2003; 13:453-9.

Hauri-Hohl A, Meyer-Böni M, Lang-Muritano M, Hauri-Hohl M, Schoenle EJ, Biason-Lauber A. Aromatase deficiency due to a functional variant in the placenta promoter and a novel missense mutation in the CYP19A1 gene. Clin Endocrinol 2011; 75:39-43.

Haus U, Späth M, Färber L. Spectrum of use and tolerability of 5-HT3 receptor antagonists. Scand J Rheumatol Suppl 2004; 119:12-8.

Hauser IA, Schaeffeler E, Gauer S et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16:1501-11.

Hauser RA. Levodopa/carbidopa/entacapone (Stalevo). Neurology 2004; 62(1 Suppl 1):64-71.

Hauta-Aho M, Tirkkonen T, Vahlberg T, Laine K. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med 2009; 41:619-28

Hautala AJ, Rankinen T, Kiviniemi AM et al. Heart rate recovery after maximal exercise is associated with acetylcholine receptor M2 (CHRM2) gene polymorphism. Am J Physiol Heart Circ Physiol 2006; 29:459-66.

Hautala AJ, Tulppo MP, Kiviniemi AM et al. Acetylcholine receptor M2 gene variants, heart rate recovery, and risk of cardiac death after an acute myocardial infarction. Ann Med 2009; 41:197-207.

Havasi V, Szolnoki Z, Talián G et al. Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke. J Mol Neurosci 2006; 29:177-83.

Havrda DE, Mai T, Chonlahan J. Enhanced antithrombotic effect of warfarin associated with low-dose alcohol consumption. Pharmacotherapy 2005; 25:303-7.

Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci 2008; 13:1634-45.

Hawas UW, Gamal-Eldeen AM, El-Toumy SA, Meyer JJ, Hussein AA. Inhibition of the initiation stage of carcinogenesis by Salvia disermas constituents. Z Naturforsch C 2009; 64:831-9.

Hawkins BT, Sykes DB, Miller DS. Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci 2010; 30:1417-25.

Hawkins NJ, Lee JH, Wong JJ, Kwok CT, Ward RL, Hitchins MP. MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Mod Pathol 2009; 22:1588-99.

Hawwa AF, McElnay JC. Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant. Expert Opin Drug Saf 2011; 10:9-22.

Hayakawa T, Nagai Y, Kahara T et al. Gln27Glu and Arg16Gly polymorphisms of the beta2-adrenergic receptor gene are not associated with obesity in Japanese men. Metabolism 2000; 49:1215-8.

Hayashi H, Fujimaki C, Inoue K, Suzuki T, Itoh K. Genetic polymorphism of C452T (T127I) in human gamma-glutamyl hydrolase in a Japanese population. Biol Pharm Bull 2007; 30:839-41.

Hayashi K, Kidouchi K, Sumi S et al. Possible prediction of adverse reactions to pyrimidine chemotherapy from urinary pyrimidine levels and a case of asymptomatic adult dihydropyrimidinuria. Clin Cancer Res 1996; 2:1937-41.

Hayashi K, Sakaki T, Kominami S, Inouye K, Yabusaki Y. Coexpression of genetically engineered fused enzyme between yeast NADPH-P450 reductase and human cytochrome P450 3A4 and human cytochrome b5 in yeast. Arch Biochem Biophys 2000; 81:164-70.

Hayashi K, Sugimoto H, Shinkyo R et al. Structure-based design of a highly active vitamin D hydroxylase from Streptomyces griseolus CYP105A1. Biochemistry 2008; 47:11964-72.

Hayashi M, Matsumoto N, Takenoshita-Nakaya S et al. Individual metabolic capacity evaluation of cytochrome P450 2C19 by protein and activity in the small intestinal mucosa of Japanese pancreatoduodenectomy patients. Biol Pharm Bull 2011; 34:71-6.

Hayashi S, Hirao A, Nakamura H, Yamamura K, Mizuno K, Yamashita H. Discovery of 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: integrated drug-design and structure-activity relationships for orally potent, metabolically stable and potential-risk reduced novel non-peptide Nociceptin/Orphanin FQ receptor agonist as antianxiety drug. Chem Biol Drug Des 2009; 74:369-81.

Hayashi S, Jayesekera D, Jayewardene A, Shah A, Thevanayagam L, Aweeka F. Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients. J Clin Pharmacol 1999; 39:1085-93.

Hayashi S, Toyoshima Y, Hasegawa M et al. Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation. Ann Neurol 2002; 51:525-30.

Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5’-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991; 110:559-65.

Hayashi Y, Ikeda U, Hashimoto T, Watanabe T, Mitsuhashi T, Shimada K. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin Electrophysiol 1999; 22:672-4.

Hayashi Y, Ushijima K, Ando H et al. Influence of a time-restricted feeding schedule on the daily rhythm of abcb1a gene expression and its function in rat intestine. J Pharmacol Exp Ther 2010; 335:418-23.

Hayes DF, Thor AD, Dressler LG et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357:1496-506.

Hayhurst GP, Strick-Marchand H, Mulet C et al. Morphogenetic competence of HNF4 alpha-deficient mouse hepatic cells. J Hepatol 2008; 49:384-95.

Hayney MS, Buck JM. Effect of age and degree of immune activation on cytochrome P450 3A4 activity after influenza immunization. Pharmacotherapy 2002; 22:1235-8.

Hayney MS, Hammes RJ, Fine JP, Bianco JA. Effect of influenza immunization on CYP3A4 activity. Vaccine 2001; 20:858-61.

Hayney MS, Muller D. Effect of influenza immunization on CYP3A4 activity in vivo. J Clin Pharmacol 2003; 43:1377-81.

Hayward BE, Barlier A, Korbonits M et al. Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 2001; 107:31-6.

Hazai E, Vereczkey L, Monostory K. Reduction of toxic metabolite formation of acetaminophen. Biochem Biophys Res Commun 2002; 291:1089-94.

He B, Li J, Wang G et al. Association of genetic polymorphisms in the type II deiodinase gene with bipolar disorder in a subset of Chinese population. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:986-90.

He F, Bi HC, Xie ZY et al. Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. Rapid Commun Mass Spectrom 2007; 21:635-43.

He H, Mennone A, Boyer JL, Cai SY. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology 2011; 53:548-57.

He J, Nishida S, Xu M, Makishima M, Xie W. PXR prevents cholesterol gallstone disease by regulating biosynthesis and transport of bile salts. Gastroenterology 2011; 140:2095-106.

He J, Qiu Z, Li N et al. Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur J Clin Pharmacol 2011; 67:701-7.

He JQ, Foreman MG, Shumansky K et al. Associations of IL6 polymorphisms with lung function decline and COPD. Thorax 2009; 64:698-704.

He JQ, Joos L, Sandford AJ. Recent developments in the genetics of asthma. Pharmacogenomics 2001; 2:329-39.

He K, Qian M, Wong H et al. N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerations. J Pharm Sci 2008; 97:2568-80.

He K, Woolf TF, Hollenberg PF. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J Pharmacol Exp Ther 1999; 288:791-7.

He K, Woolf TF, Kindt EK, Fielder AE, Talaat RE. Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction. Biochem Pharmacol 2001; 62:191-8.

He L, He F, Bi H et al. Isoform-selective inhibition of chrysin towards human cytochrome P450 1A2. Kinetics analysis, molecular docking, and molecular dynamics simulations. Bioorg Med Chem Lett 2010; 20:6008-12.

He L, Yang J, Hu L. Transmembrane transport activity of paclitaxel regulated by fangchinoline in MDR1-mDCK II cells. Zhongguo Zhong Yao Za Zhi 2010; 35:1478-81.

He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 1999; 372:16-28.

He N, Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther 2004; 11:206-12.

He N, Huang SL, Zhu RH et al. Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent. Xenobiotica 2003; 33:211-21.

He N, Xie HG, Collins X, Edeki T, Yan Z. Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes. Clin Exp Pharmacol Physiol 2006; 33:813-5.

He N, Zhang WQ, Shockley D, Edeki T. Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes. Eur J Clin Pharmacol 2002; 57:847-51.

He P, Court MH, Greenblatt DJ, von Moltke LL. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 2005; 77:373-87.

He P, Court MH, Greenblatt DJ, von Moltke LL. Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab Dispos 2006; 34:1198-207.

He P, Court MH, Greenblatt DJ, von Moltke LL. Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity. J Clin Pharmacol 2006; 46:1356-69.

He Q, Zhang G, Hou D et al. Overexpression of sorcin results in multidrug resistance in gastric cancer cells with up-regulation of P-gp. Oncol Rep 2011; 25:237-43.

He S, Liu F, Xie Z, Zu X, Xu W, Jiang Y. P-glycoprotein/MDR1 regulates pokemon gene transcription through p53 expression in human breast cancer cells. Int J Mol Sci 2010; 11:3309-51.

He SM, Li CG, Liu JP, Chan E, Duan W, Zhou SF. Disposition pathways and pharmacokinetics of herbal medicines in humans. Curr Med Chem 2010; 17:4072-113.

He SM, Li R, Kanwar JR, Zhou SF. Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Curr Med Chem 2011; 18:439-81.

He SM, Zhou ZW, Li XT, Zhou SF. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. Curr Med Chem 2011; 18:667-713.

He W, Li K. Incidence of genetic polymorphisms involved in lipid metabolism among Chinese patients with osteonecrosis of the femoral head. Acta Orthop 2009; 80:325-9.

He X, Huang Y, Li B, Gong CX, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer’s disease. Neurobiol Aging 2010; 31:398-408.

He X, Luo X, Liu Z, Hu G, Cheng Z. Identification of the human liver cytochrome P450 isoenzymes responsible for the 5-methylhydroxylation of the novel anti-fibrotic drug AKF-PD. Xenobiotica 2011; 41:844-50.

He XJ, Yamauchi H, Suzuki K, Ueno M, Nakayama H, Doi K. Gene expression profiles of drug-metabolizing enzymes (DMEs) in rat liver during pregnancy and lactation. Exp Mol Pathol 2007; 83:428-34.

He XJ, Zhao LM, Qiu F, Sun YX, Li-Ling J. Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects. Pharmacol Rep 2009; 61:843-50.

He XY, Tang L, Wang SL, Cai QS, Wang JS, Hong JY. Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. Int J Cancer 2006; 118:2665-71.

He YA, Roussel F, Halpert JR. Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. Arch Biochem Biophys 2003; 409:92-101.

He YJ, Brockmöller J, Schmidt H, Roots I, Kirchheiner J. CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? J Anal Toxicol 2008; 32:178-82.

He YJ, Zhang W, Tu JH et al. Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. Drug Metab Dispos 2008; 36:1453-6.

He YY, Zhang R, Shao XY et al. Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients. Acta Pharmacol Sin 2008; 29:983-9.

He Z, Hu Y, Feng L et al. Polymorphisms in the HBB gene relate to individual cardiorespiratory adaptation in response to endurance training. Br J Sports Med 2006; 40:998-1002.

Head E, Doran E, Nistor M et al. Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis 2011; 23:399-409.

Head MW, Northcott V, Rennison K et al. Prion protein accumulation in eyes of patients with sporadic and variant Creutzfeldt-Jakob disease. Invest Ophthal Vis Sci 2003; 44:342-6.

Head MW, Tissingh G, Uitdehaag BM et al. Sporadic Creutzfeldt-Jakob disease in a joung Dutch valine homozygote: atypical molecular phenotype. Ann Neurol 2001; 50:258-61.

Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 2008; 117:207-31.

Healan-Greenberg C, Waring JF, Kempf DJ, Blomme EA, Tirona RG, Kim RB. A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab Dispos 2008; 36:500-7.

Healy KD, Vanhooke JL, Prahl JM, DeLuca HF. Parathyroid hormone decreases renal vitamin D receptor expression in vivo. Proc Nat Acad Sci USA 2005; 102:4724-8.

Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients withmetastatic refractory solid tumors. Invest New Drugs 2008; 26:59-65.

Hebeda CB, Pinedo FJ, Vinolo MA, Curi R, Farsky SH. Hydroquinone stimulates inflammatory functions in microvascular endothelial cells via NF-κB nuclear activation. Basic Clin Pharmacol Toxicol 2011; 109:372-80.

Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997; 27:201-214.

Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39:91-6.

Heck A, Lieb R, Ellgas A et al. Investigation of 17 candidate genes for personality traits confirms effects of the HTR2A gene on novelty seeking. Genes Brain Behav 2009; 8:464-72.

Hechler B, Freund M, Alame G et al. The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/GPIIbIIIa antagonist, exceeds that of the co-administrated parent compounds. J Pharmacol Exp Ther 2011; 338:412-20.

Hechler B, Gachet C. Comparison of two murine models of thrombosis induced by atherosclerotic plaque injury. Thromb Haemost 2011; 105 Suppl 1:3-12.

Hedaya MA, El-Afify DR, El-Maghraby GM. The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. Biopharm Drug Dispos 2006; 27:103-10.

Hedenmalm K, Lindh JD, Säwe J, Rane A. Increased liability of tramadol-warfarin interaction in individuals with mutations in the cytochrome P450 2D6 gene. Eur J Clin Pharmacol 2004; 60:369-72.

Hedenmalm K, Sundgren M, Granberg K, Spigset O, Dahlqvist R. Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity. Ther Drug Monit 1997; 19:643-9.

Hediger MA. New view at C. Nat Med 2002; 8:445-6.

Hedman M, Antikainen M, Holmberg C et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol 2006; 61:706-15.

Heemstra KA, Hoftijzer HC, van der Deure WM et al. The Thr92Ala polymorphism in the type 2 deiodinase is not associated with thyroxine dose in athyroid patients or patients with Hashimoto thyroiditis. Clin Endocrinol 2009; 71:279-83.

Heffeter P, Jakupec MA, Körner W et al. Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochem Pharmacol 2007; 73:1873-86.

Hegde RS, Tremblay P, Groth D, DeArmond SJ, Prusiner SB, Lingappa VR. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 1999; 402:732-6.

Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 2006; 147 Suppl 2:80-7.

Hegedus C, Ozvegy-Laczka C, Apáti A et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 2009; 158:1153-64.

Hegele RA, Ban MR, Hsueh N et al. A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. Hum Mol Genet 2009; 18:4189-94.

Hegele RA, Harris SB, Hanley AJ, Zinman B. Association between AGT T235 variant and microalbuminuria in Canadian Oji-Cree with type 2 diabetes mellitus. Clin Biochem 1999; 32:201-5.

Hegele RA, Pollex RL. Apolipoprotein A-V genetic variation and plasma lipoprotein response to fibrates. Arterioscler Thromb Vasc Biol 2007; 27:1224-7.

Hegele RA, Vezina C, Moorjani S et al. A hepatic lipase gene mutation associated with heritable lipolytic deficiency. J Clin Endocrinol Metab 1991; 72:730-2.

Hegener HH, Lee IM, Cook NR, Ridker PM, Zee RY. Association of adiponectin gene variations with risk of incident myocardial infarction and ischemic stroke: a nested case-control study. Clin Chem 2006; 52:2021-7.

Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.

Heid IM, Henneman P, Hicks A et al. Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. Atherosclerosis 2010; 208:412-20.

Heidbuchel H, Verhamme P. Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice. Acta Cardiol 2010; 65:491-7.

Heidrich J, Wellmann J, Döring A, Illig T, Keil U. Alcohol consumption, alcohol dehydrogenase and risk of coronary heart disease in the MONICA/KORA-Augsburg cohort 1994/1995-2002. Eur J Cardiovasc Prev Rehabil 2007; 14:769-74.

Heikinheimo O. Clinical pharmacokinetics of mifepristone. Clin Pharmacokinet 1997; 33:7-17.

Heikinheimo O, Kekkonen R, Lähteenmäki P. The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception 2003; 68:421-6.

Heikkilä T, Thirumalairajan S, Davies M et al. The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg Med Chem Lett 2006; 16:88-92.

Heim MH, Meyer UA. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992; 14:49-58.

Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002; 506-507:65-77.

Hein DW, Boukouvala S, Grant DM, Minchin RF, Sim E. Changes in consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenet Genomics 2008; 18:367-8.

Hein DW, Doll MA, Fretland AJ et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000; 9:29-42.

Heinig R, Böttcher MF. Pharmacokinetics of escalating doses of intravenous repinotan in healthy male volunteers. Clin Drug Investig 2005; 25:115-23.

Heinig R. Clinical pharmacokinetics of nisoldipine coat-core. Clin Pharmacokinet 1998; 35:191-208.

Heinonen S, Korhonen S, Helisalmi S et al. Associations between two single nucleotide polymorphisms in the adiponectin gene and polycystic ovary syndrome. Gynecol Endocrinol 2005; 21:165-9.

Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299:708-10.

Heinrich MC, Maki RG, Corless CL et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26:5352-9.

Heiser V, Scherzinger E, Boeddrich A et al. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington’s disease therapy. Proc Nat Acad Sci USA 2000; 97:6739-44.

Heiskanen T, Backman JT, Neuvonen M, Kontinen VK, Neuvonen PJ, Kalso E. Itraconazole, a potent inhibitor of P-glycoprotein, moderately increases plasma concentrations of oral morphine. Acta Anaesthesiol Scand 2008; 52:1319-26.

Hejmej A, Kotula-Balak M, Galas J, Bilińska B. Effects of 4-tert-octylphenol on the testes and seminal vesicles in adult male bank voles. Reprod Toxicol 2011; 31:95-105.

Helbecque N, Codron V, Cottel D, Amouyel P. An age effect on the association of common variants of ACE with Alzheimer’s disease. Neurosci Lett 2009; 461:181-4.

Helgadottir A, Manolescu A, Helgason A et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006; 38:68-74.

Helgadottir A, Thorleifsson G, Magnusson KP et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 2008; 40:217-24.

Helisalmi S, Hiltunen M, Vepsäläinen S et al. Genetic variation in apolipoprotein D and Alzheimer’s disease. J Neurol 2004; 251:951-7.

Helmig S, Döhrel J, Schneider J. Decreased Cyp2E1 mRNA expression in human leucocytes in patients with fibrotic and inflammatory lung diseases. Int J Mol Med 2010; 26:143-9.

Helmig S, Seelinger JU, Döhrel J, Schneider J. RNA expressions of AHR, ARNT and CYP1B1 are influenced by AHR Arg554Lys polymorphism. Mol Genet Metab 2011; 104:180-4.

Helmig S, Seelinger JU, Philipp-Gehlhaar M, Döhrel J, Schneider J. Cyp1B1 mRNA expression in correlation to cotinine levels with respect to the Cyp1B1 L432V gene polymorphism. Eur J Epidemiol 2010; 25:867-73.

Helsby N, Goldthorpe M, Gow P, de Zoysa J. Is the prevalence of CYP2C19 genetic variants different in Pacific people than in New Zealand Europeans? N Z Med J 2010; 123:37-41.

Helsby NA, Hui CY, Goldthorpe MA et al. The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. Br J Clin Pharmacol 2010; 70:844-53.

Helsby NA, Lo WY, Sharples K et al. CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype. Br J Cancer 2008; 99:1251-5.

Helsby NA, Lo WY, Thompson P, Laking GR. Do 5-fluorouracil therapies alter CYP2C19 metaboliser status? Cancer Chemother Pharmacol 2010; 66:405-7.

Helldén A, Bergman U, Engström Hellgren K et al. Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9. Eur J Clin Pharmacol 2010; 66:791-5.

Hellinger E, Bakk ML, Pócza P, Tihanyi K, Vastag M. Drug penetration model of vinblastine-treated Caco-2 cultures. Eur J Pharm Sci 2010; 41:96-106.

Hellman K, Roos E, Osterlund A et al. Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity. Br J Clin Pharmacol 2003; 56:337-40.

Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 2007; 100:23-30.

Hellum BH, Nilsen OG. The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol. Basic Clin Pharmacol Toxicol 2007; 101:350-8.

Hellum BH, Nilsen OG. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol 2008; 102:466-75.

Hellum BH, Tosse A, Hoybakk K, Thomsen M, Rohloff J, Georg Nilsen O. Potent in vitro inhibition of CYP3A4 and P-Glycoprotein by Rhodiola rosea. Planta Med 2010; 76:331-8.

Hemauer SJ, Patrikeeva SL, Nanovskaya TN, Hankins GD, Ahmed MS. Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am J Obstet Gynecol 2010; 202:383-7.

Hemauer SJ, Patrikeeva SL, Wang X et al. Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol 2010; 80:1080-6.

Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002; 3:13-37.

Hemeryck A, de Vriendt C, Belpaire FM. Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. J Clin Psychopharmacol 2000; 20:428-34.

Henderson AS, Easteal S, Jorm AF et al. Apolipoprotein E allele e4, dementia, and cognitive decline in a population sample. Lancet 1995; 346:1387-90.

Henderson GL, Harkey MR, Gershwin ME, Hackman RM, Stern JS, Stresser DM. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 1999; 65:209-14.

Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54:349-56.

Henderson MC, Miranda CL, Stevens JF, Deinzer ML, Buhler DR. In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus. Xenobiotica 2000; 30:235-51.

Henderson SO, Simma-Chiang V, Lee C, Calder K, Mack WJ. Asthma: Effect of genotype on Response to Therapy in the Emergency Department. West J Emerg Med 2007; 8:73-7.

Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab 2009; 6:31.

Hendig D, Langmann T, Kocken S et al. Gene expression profiling of ABC transporters in dermal fibroblasts of pseudoxanthoma elasticum patients identifies new candidates involved in PXE pathogenesis. Lab Invest 2008; 88:1303-15.

Hendig D, Langmann T, Zarbock R, Schmitz G, Kleesiek K, Götting C. Characterization of the ATP-binding cassette transporter gene expression profile in Y79: a retinoblastoma cell line. Mol Cell Biochem 2009; 328:85-92.

Hendset M, Haslemo T, Rudberg I, Refsum H, Molden E. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry 2006; 39:121-7.

Hendset M, Hermann M, Lunde H, Refsum H, Molden E. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 2007; 63:1147-51.

Hendset M, Molden E, Enoksen TB, Refsum H, Hermann M. The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data. Ther Drug Monit 2010; 32:787-90.

Heneka MT, Kummer MP, Weggen S et al. Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer’s disease. Curr Alzheimer Res 2011; 8:115-31.

Heneka MT, Nadrigny F, Regen T et al. Locus ceruleus controls Alzheimer’s disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci USA 2010; 107:6058-63.

Henkel A, Wei Z, Cohen DE, Green RM. Mice overexpressing hepatic Abcb11 rapidly develop cholesterol gallstones. Mamm Genome 2005; 16:903-8.

Henkel AS, Anderson KA, Dewey AM, Kavesh MH, Green RM. A chronic high-cholesterol diet paradoxically suppresses hepatic CYP7A1 expression in FVB/NJ mice. J Lipid Res 2011; 52:289-98.

Henkens T, Snykers S, Vinken M et al. Preservation of hepatocellular functionality in cultures of primary rat hepatocytes upon exposure to 4-Me2N-BAVAH, a hydroxamate-based HDAC-inhibitor. Toxicol In Vitro 2011; 25:100-9.

Henneman P, Aulchenko YS, Frants RR et al. Genetic architecture of plasma adiponectin overlaps with the genetics of metabolic syndrome-related traits. Diabetes Care 2010; 33:908-13.

Hennessy M, Kelleher D, Spiers JP et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002; 53:75-82.

Hennessy S, Leonard CE, Newcomb C, Kimmel SE, Bilker WB. Cisapride and ventricular arrhythmia. Br J Clin Pharmacol 2008; 66:375-85.

Henningsson A, Marsh S, Loos WJ et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005; 11:8097-104.

Henriette Tanja L, Guchelaar HJ, Gelderblom H. Pharmacogenetics in chemotherapy of colorectal cancer. Best Pract Res Clin Gastroenterol 2009; 23:257-73.

Henriksen EJ, Dokken BB. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets 2006; 7:1435-41.

Henriksen RA, Mann KG. Substitution of valine for glycine-558 in the congenital dysthrombin thrombin Quick II alters primary substrate specificity. Biochemistry 1989; 28:2078-82.

Henriques AG, Domingues SC, Fardilha M, da Cruz e Silva EF, da Cruz e Silva OA. Sodium azide and 2-deoxy-D-glucose-induced cellular stress affects phosphorylation-dependent AbetaPP processing. J Alzheimers Dis 2005; 7:201-12.

Henríquez-Hernández LA, Murias-Rosales A, González-Hernández A, de León AC, Díaz-Chico N, Fernández-Pérez L. Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy. Cancer Epidemiol 2010; 34:634-8.

Henríquez-Hernández LA, Pérez LF, Hernández AG, de León AC, Díaz-Chico B, Rosales AM. TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy. Cancer Epidemiol 2010; 34:490-3.

Henry NL, Banerjee M, Wicha M et al. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer 2011. doi:10. 1002/cncr. 26230.

Henry NL, Rae JM, Li L, Azzouz F et al. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat 2009; 117:571-5.

Hensel A, Deters AM, Müller G, Stark T, Wittschier N, Hofmann T. Occurrence of N-phenylpropenoyl-L-amino acid amides in different herbal drugs and their influence on human keratinocytes, on human liver cells and on adhesion of Helicobacter pylori to the human stomach. Planta Med 2007; 73:142-50.

Henshall J, Galetin A, Harrison A, Houston JB. Comparative analysis of CYP3A heteroactivation by steroid hormones and flavonoids in different in vitro systems and potential in vivo implications. Drug Metab Dispos 2008; 36:1332-40.

Henskens LH, Kroon AA, van der Schouw YT et al. Renin-angiotensin system and nitric oxide synthase gene polymorphisms in relation to stroke. Am J Hypertens 2007; 20:764-70.

Hensley K, Barnes LL, Christov A et al. Analysis of postmortem ventricular cerebrospinal fluid from patients with and without dementia indicates association of vitamin E with neuritic plaques and specific measures of cognitive performance. J Alzheimers Dis 2011; 24:767-74.

Heo GY, Bederman I, Mast N, Liao WL, Turko IV, Pikuleva IA. Conversion of 7-ketocholesterol to oxysterol metabolites by recombinant CYP27A1 and retinal pigment epithelial cells. J Lipid Res 2011; 52:1117-27.

Heppner C, Kester MB, Agarwal SK et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet 1997; 16:375-8.

Heravi RE, Ramezani M, Behravan J. Association between nicotine metabolism and CYP2A6*1 and CYP2A6*4 genotypes in an Iranian population. DNA Cell Biol 2010; 29:369-73.

Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract 2004; 58:612-24.

Herbst J, Anthony M, Stewart J et al. Multiplexing a high-throughput liability assay to leverage efficiencies. Assay Drug Dev Technol 2009; 7:294-303.

Heredia A, Amoroso A, Davis C et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA 2003; 100:10411-6.

Heredia A, Latinovic O, Gallo RC et al. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci USA 2008; 105:20476-81.

Herfarth H, Pollok-Kopp B, Göke M, Press A, Oppermann M. Polymorphism of CC chemokine receptors CCR2 and CCR5 in Crohn’s disease. Immunol Lett 2001; 77:113-7.

Herman D, Locatelli I, Grabnar I et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005; 5:193-202.

Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) in a patient on warfarin therapy. Thromb Haemost 2006; 95:192-4.

Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 2006; 95:782-7.

Hermann M, Hendset M, Fosaas K, Hjerpset M, Refsum H. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. Eur J Clin Pharmacol 2008; 64:483-7.

Hermann M, Kase ET, Molden E, Christensen H. Evaluation of microsomal incubation conditions on CYP3A4-mediated metabolism of cyclosporine A by a statistical experimental design. Curr Drug Metab 2006; 7:265-71.

Hermann R, Borlak J, Munzel U et al. The role of Gilbert’s syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine. Pharmacogenomics J 2006; 6:211-9.

Hermann R, Turpeinen H, Laine AP et al. HLA DR-DQ-encoded genetic determinants of childhood-onset type 1 diabetes in Finland: an analysis of 622 nuclear families. Tissue Antigens 2003; 62:162-9.

Hernández A, Xamena N, Sekaran C et al. High arsenic metabolic efficiency in AS3MT287Thr allele carriers. Pharmacogenet Genomics 2008; 18:349-55.

Hernández A, Xamena N, Surrallés J et al. Role of the Met(287)Thr polymorphism in the AS3MT gene on the metabolic arsenic profile. Mutat Res 2008; 637:80-92.

Hernandez D, Addou S, Lee D, Orengo C, Shephard EA, Phillips IR. Trimethylaminuria and a human FMO3 mutation database. Hum Mutat 2003; 22:209-13.

Hernandez D, Janmohamed A, Chandan P, Omar BA, Phillips IR, Shephard EA. Deletion of the mouse Fmo1 gene results in enhanced pharmacological behavioural responses to imipramine. Pharmacogenet Genomics 2009; 19:289-99.

Hernandez D, Melidoni AN, Phillips R, Shephard EA. Microinjection of targeted embryonic stem cells and establishment of knockout mouse lines for Fmo genes. Methods Mol Biol 2006; 320:329-41.

Hernández Prada JA, Ferreira AJ, Katovich MJ et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008; 51:1312-7.

Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet 2003; 118:60-5.

Herraiz T, Guillén H, Arán VJ, Idle JR, Gonzalez FJ. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6. Toxicol Appl Pharmacol 2006; 216:387-98.

Herraiz T, Guillén H, Arán VJ. Oxidative metabolism of the bioactive and naturally occurring beta-carboline alkaloids, norharman and harman, by human cytochrome P450 enzymes. Chem Res Toxicol 2008; 21:2172-80.

Herrera J, Amigo L, Husche C et al. Fecal bile acid excretion and messenger RNA expression levels of ileal transporters in high risk gallstone patients. Lipids Health Dis 2009; 8:53.

Herrero MJ, Almenar L, Jordán C, Sánchez I, Poveda JL, Aliño SF. Clinical interest of pharmacogenetic polymorphisms in the immunosuppressive treatment after heart transplantation. Transplant Proc 2010; 42:3181-2.

Herrero MJ, Sánchez-Plumed J, Galiana M, Bea S, Marqués MR, Aliño SF. Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation. Transplant Proc 2010; 42:3134-6.

Herring A, Yasin H, Ambrée O, Sachser N, Paulus W, Keyvani K. Environmental enrichment counteracts Alzheimer’s neurovascular dysfunction in TgCRND8 mice. Brain Pathol 2008; 18:32-9.

Herrington DM, Howard TD, Hawkins GA et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002; 346:967-74.

Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000; 356:2069-70.

Herrlin K, Yasui-Furukori N, Tybring G, Widén J, Gustafsson LL, Bertilsson L. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol 2003; 56:415-21.

Herrlinger KR, Cummings JR, Barnardo MC, Schwab M, Ahmad T, Jewell DP. The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet Genomics 2005; 15:705-11.

Herrlinger KR, Koc H, Winter S et al. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther 2011; 89:422-8.

Hersh EV, Moore PA. Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc 2004; 135:298-311.

Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther 2007; 29:2477-97.

Hershfield MS. New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 2005; 35:25-30.

Hertig A, Liere P, Chabbert-Buffet N et al. Steroid profiling in preeclamptic women: evidence for aromatase deficiency. Am J Obstet Gynecol 2010; 203:477. e1-9.

Herzberg I, Valencia-Duarte AV, Kay VA et al. Association of DRD2 variants and Gilles de la Tourette syndrome in a family-based sample from a South American population isolate. Psychiatr Genet 2010; 20:179-83.

Herzig MC, Winkler DT, Burgermeister P et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 2004; 7:954-60.

Herzog M, Storch CH, Gut P et al. Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity. Naunyn Schmiedebergs Arch Pharmacol 2011; 383:1-11.

Hesse C, Eisenach JH. Genetic variation in the beta(2)-adrenergic receptor: impact on intermediate cardiovascular phenotypes. Curr Pharmacogenomics Person Med 2008; 6:160-70.

Hesse LM, He P, Krishnaswamy S et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004; 14:225-38.

Hesse LM, Sakai Y, Vishnuvardhan D, Li AP, von Moltke LL, Greenblatt DJ. Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. J Pharm Pharmacol 2003; 55:1229-39.

Hesse LM, Venkatakrishnan K, Court MH et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000; 28:1176-83.

Hesse LM, Venkatakrishnan K, von Moltke LL, Shader RI, Greenblatt DJ. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos 2001; 29:133-40.

Hesse LM, von Moltke LL, Greenblatt DJ. Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 2003; 17:513-32.

Hesse M, Kondo CS, Clark RB et al. Dilated cardiomyopathy is associated with reduced expression of the cardiac sodium channel Scn5a. Cardiovasc Res 2007; 75:498-509.

Hessel S, Lampen A. All-trans retinoic acid enhances the transport of phase II metabolites of benzo[a]pyrene by inducing the breast cancer resistance protein expression in Caco-2 cells. Toxicol Lett 2010; 197:151-5.

Hesselink DA, van Gelder T, van Schaik RH et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76:545-56.

Hesselink DA, van Schaik RH, Nauta J, van Gelder T. A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine. Pharmacogenomics 2008; 9:783-9.

Hesselink DA, van Schaik RH, van der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74:245-54.

Hester EK, Chandler HV, Sims KM. Fosamprenavir: drug development for adherence. Ann Pharmacother 2006; 40:1301-10.

Hetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH, Samani NJ. Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol 2005; 25:252-7.

Hettinger JA, Liu X, Holden JJ. The G22A polymorphism of the ADA gene and susceptibility to autism spectrum disorders. J Autism Dev Disord 2008; 38:14-9.

Heubner M, Riemann K, Otterbach F et al. The haplotype of two FSHR polymorphisms in ovarian cancer-a potential role of ethnology in risk modification. Gynecol Oncol 2009; 112:486-9.

Heutink P, Stevens M, Rizzu P et al. Hereditary frontotemporal dementia is linked to chromosome 17q21-q22: a genetic and clinicopathological study of three Dutch families. Ann Neurol 1997; 41:150-9.

Heverin M, Meaney S, Brafman A et al. Studies on the cholesterol-free mouse: strong activation of LXR-regulated hepatic genes when replacing cholesterol with desmosterol. Arterioscler Thromb Vasc Biol 2007; 27:2191-7.

Hevir N, Sinkovec J, Rižner TL. Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: lower levels of CYP1B1 and increased expression of S-COMT. Mol Cell Endocrinol 2011; 331:158-67.

Heward JM, Allahabadia A, Armitage M et al. The development of Graves’ disease and the CTLA-4 gene on chromosome 2q33. J Clin Endocrinol Metab 1999; 84:2398-401.

Hewes JC, Riddy D, Morris RW, Woodrooffe AJ, Davidson BR, Fuller B. A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: the effects of prior exposure to chemotherapy. J Hepatol 2006; 45:263-70.

Hewitt AJ, Walker KR, Kobus SM, Poklewska-Koziell M, Reynolds JN, Brien JF. Differential effects of chronic ethanol exposure on cytochrome P450 2E1 and the hypothalamic-pituitary-adrenal axis in the maternal-fetal unit of the guinea pig. Neurotoxicol Teratol 2010; 32:164-70.

Hewitt NJ, Lloyd S, Hayden M et al. Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes. Chem Biol Interact 2002; 142:73-82.

Hey JA, del Prado M, Kreutner W, Egan RW. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. Arzneimittelforschung 1996; 46:159-63.

Heyn H, White RB, Stevens JC. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 1996; 24:948-54.

Hickey NJ, Crump D, Jones SP, Kennedy SW. Effects of 18 perfluoroalkyl compounds on mRNA expression in chicken embryo hepatocyte cultures. Toxicol Sci 2009; 111:311-20.

Hickling KC, Hitchcock JM, Oreffo V et al. Evidence of oxidative stress and associated DNA damage, increased proliferative drive, and altered gene expression in rat liver produced by the cholangiocarcinogenic agent furan. Toxicol Pathol 2010; 38:230-43.

Hichiya H, Tanaka-Kagawa T, Soyama A et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos 2005; 33:630-6.

Hidalgo J, Florit S, Giralt M, Ferrer B, Keller C, Pilegaard H. Transgenic mice with astrocyte-targeted production of interleukin-6 are resistant to high-fat diet-induced increases in body weight and body fat. Brain Behav Immun 2010; 24:119-26.

Hider SL, Thomson W, Mack LF, Armstrong DJ, Shadforth M, Bruce IN. Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. Rheumatology 2008; 47:1156-9.

Hidestrand M, Oscarson M, Salonen JS et al. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson’s disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos 2001; 29:1480-4.

Hidestrand M, Shankar K, Ronis MJ, Badger TM. Effects of light and dark beer on hepatic cytochrome P-450 expression in male rats receiving alcoholic beverages as part of total enteral nutrition. Alcohol Clin Exp Res 2005; 29:888-95.

Hiebert PR, Boivin WA, Abraham T, Pazooki S, Zhao H, Granville DJ. Granzyme B contributes to extracellular matrix remodeling and skin aging in apolipoprotein E knockout mice. Exp Gerontol 2011; 46:489-99.

Hien TT, Kim HG, Han EH, Kang KW, Jeong HG. Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-kappaB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells. Mol Nutr Food Res 2010; 54:918-28.

Hiéronimus S, Lussiez V, Le Duff F, Ferrari P, Bständig B, Fénichel P. Klinefelter’s syndrome and bone mineral density: is osteoporosis a constant feature? Ann Endocrinol 2011; 72:14-8.

Hieronymus J Derijks, Ronald HB, Meyboom RH et al. The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol 2008; 64:531–538.

Hietala M, Henningson M, Ingvar C, Jönsson PE, Rose C, Jernström H. Natural remedy use in a prospective cohort of breast cancer patients in southern Sweden. Acta Oncol 2011; 50:134-43.

Hietala M, Sandberg T, Borg A, Olsson H, Jernström H. Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women. Hum Reprod 2007; 22:83-91.

Higasa S, Tsujimura M, Hiraoka M et al. Polymorphism of glutathione S-transferase P1 gene affects human vitamin C metabolism. Biochem Biophys Res Commun 2007; 364:708-13.

Higasa S, Tsujimura M, Hiraoka M et al. Genetic polymorphisms of xenobiotic enzymes affect human vitamin C excretion. Asia Pac J Public Health 2008; 20 Suppl:70-9.

Higashi MK, Veenstra DL, Kondo LM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690-8.

Higashi N, Matsumura Y, Mizuno F et al. Enhanced expression of ATP-binding cassette transporter A1 in non-rafts decreases the sensitivity of vascular endothelial cells to Shiga toxin. Microb Pathog 2010; 49:141-52.

Higashikuni Y, Sainz J, Nakamura K et al. The ATP-binding cassette transporter BCRP1/ABCG2 plays a pivotal role in cardiac repair after myocardial infarction via modulation of microvascular endothelial cell survival and function. Arterioscler Thromb Vasc Biol 2010; 30:2128-35.

Higashimori M, Tatro JB, Moore KJ, Mendelsohn ME, Galper JB, Beasley D. Role of toll-like receptor 4 in intimal foam cell accumulation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2011; 31:50-7.

Highet AR, Gibson CS, Goldwater PN. Variant interleukin 1 receptor antagonist gene alleles in sudden infant death syndrome. Arch Dis Child 2010; 95:1009-12.

Higuchi M, Lee VMY, Trojanowski JQ. Tau and axonopathy in neurodegenerative disorders. NeuroMolec Med 2002; 2:131-50.

Higuchi S, Matsushita S, Hasegawa Y, Maramatsu T, Arai H, Hayashida M. Apolipoprotein E e4 Allele and pupillary response to tropicamide. Am J Psychiatry 1997; 154:694-6.

Higuchi S, Muramatsu T, Matsushita S, Murayama M, Hayashida M. Polymorphisms of ethanol-oxidizing enzymes in alcoholics with inactive ALDH2. Hum Genet 1996; 97:413-34.

Higuchi S, Ohta S, Matsushita S et al. NOS3 polymorphism not associated with Alzheimer’s disease in Japanese. Ann Neurol 2000; 48:685.

Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002; 30:853-8.

Hikage S, Nakayama K, Saito T et al. Cytotoxicity of bisphenol A glycidyl methacrylate on cytochrome P450-producing cells. J Oral Rehabil 2003; 30:544-9.

Hilal L, Boutayeb S, Serrou A et al. Screening of CYP1B1 and MYOC in Moroccan families with primary congenital glaucoma: three novel mutations in CYP1B1. Mol Vis 2010; 16:1215-26.

Hildebrand A, Pfeiffer E, Metzler M. Aromatic hydroxylation and catechol formation: a novel metabolic pathway of the growth promotor zeranol. Toxicol Lett 2010; 192:379-86.

Hildebrandt MA, Carrington DP, Thomae BA et al. Genetic diversity and function in the human cytosolic sulfotransferases. Pharmacogenomics J 2007; 7:133-43.

Hildebrandt MA, Salavaggione OE, Martin YN et al. Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies. Biochem Biophys Res Commun 2004; 321:870-8.

Hildich-Maguire P, Trettel F, Passani L, Auerbach A, Persichetti F, McDonald ME. Huntington: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Molec Genet 2000; 9:2789-97.

Hill AF, Butterworth RJ, Joirier S et al. Investigation of variant Creutzfeldt Jakob disease and other human prion disease with tonsil biopsy samples. Lancet 1999; 353:183-9.

Hill AF, Joiner S, Wadsworth JDF et al. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain 2003; 126:1333-46.

Hill AV, Allsopp CE, Kwiatkowski D et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991; 352:595-600.

Hill CE, Wickliffe JK, Guerin AT et al. The L84F polymorphism in the O6-Methylguanine-DNA-Methyltransferase (MGMT) gene is associated with increased hypoxanthine phosphoribosyltransferase (HPRT) mutant frequency in lymphocytes of tobacco smokers. Pharmacogenet Genomics 2007; 17:743-53.

Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006; 75:402-15.

Hill JW, Levine JE. Abnormal response of the neuropeptide Y-deficient mouse reproductive axis to food deprivation but not lactation. Endocrinology 2003; 144:1780-6.

Hille UE, Hu Q, Vock C et al. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls. Eur J Med Chem 2009; 44:2765-75.

Hilleret H, Voirol P, Bovier P et al. Very long half-life of paroxetine following intoxication in an extensive cytochrome P4502D6 metabolizer. Ther Drug Monit 2002; 24:567-9.

Hillermann R, Carelse K, Gebhardt GS. The Glu29-to-Asp variant of the endothelial nitric oxide synthase gene is associated with an increased risk for abruptio placentae in pre-eclampsia. J Hum Genet 2005; 50:415-9.

Hindorff LA, Heckbert SR, Tracy R et al. Angiotensin II type 1 receptor polymorphisms in the cardiovascular health study: relation to blood pressure, ethnicity, and cardiovascular events. Am J Hypertens 2002; 15:1050-6.

Hindorff LA, Lemaitre RN, Smith NL et al. Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogenet Genomics 2008; 18:677-82.

Hines LM, Stampfer MJ, Ma J et al. Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. New Eng J Med 2001; 344:549-55.

Hines RN. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol 2007; 21:169-75.

Hines RN, Luo Z, Hopp KA, Cabacungan ET, Koukouritaki SB, McCarver DG. Genetic variability at the human FMO1 locus: significance of a basal promoter yin yang 1 element polymorphism (FMO1*6). J Pharmacol Exp Ther 2003; 306:1210-8.

Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002; 300:355-60.

Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995; 13:1602-9.

Hingorani AD, Liang CF, Fatibene J et al. A common variant of the endothelial nitric oxide synthase (Glu298→Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999; 100:1515-20.

Hinks A, Eyre S, Ke X et al. Association of the AFF3 gene and IL2/IL21 gene region with juvenile idiopathic arthritis. Genes Immun 2010; 11:194-8.

Hintermann E, Holdener M, Bayer M et al. Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. J Autoimmun 2011. doi:10. 1016/j. jaut. 2011. 06. 005.

Hioki T, Fukami T, Nakajima M, Yokoi T. Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis. Drug Metab Dispos 2011; 39:1345-52.

Hippalgaonkar K, Srirangam R, Avula B, Khan IA, Majumdar S. Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. Drug Metab Dispos 2010; 38:1790-7.

Hippius M, Farker K, Helble S, Hoffmann A. Assessment of ADRs associated with lipid-lowering agents recorded in the Department of Internal Medicine, University Hospital, Jena. Int J Clin Pharmacol Ther 2002; 40:97-101.

Hiraga T, Ito S, Nakamura H. Side population in MDA-MB-231 human breast cancer cells exhibits cancer stem cell-like properties without higher bone-metastatic potential. Oncol Rep 2011; 25:289-96.

Hirai T, Fukui Y, Motojima K. PPARalpha agonists positively and negatively regulate the expression of several nutrient/drug transporters in mouse small intestine. Biol Pharm Bull 2007; 30:2185-90.

Hirai T, Okuma C, Harada C et al. Development of amygdaloid kindling in histidine decarboxylase-deficient and histamine H1 receptor-deficient mice. Epilepsia 2004; 45:309-13.

Hiraishi K, Yoshimoto T, Tsuchiya K et al. Clinicopathological features of primary aldosteronism associated with subclinical Cushing’s syndrome. Endocr J 2011; 58:543-51.

Hirakawa S, Imaeda D, Nakayama K et al. Integrative assessment of potential effects of dioxins and related compounds in wild Baikal seals (Pusa sibirica): Application of microarray and biochemical analyses. Aquat Toxicol 2011; 105:89-99.

Hiraki M, Kitajima Y, Koga Y et al. Aberrant gene methylation is a biomarker for the detection of cancer cells in peritoneal wash samples from advanced gastric cancer patients. Ann Surg Oncol 2011; 18:3013-9.

Hiraki M, Kitajima Y, Nakafusa Y et al. CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients. Oncol Rep 2010; 23:191-7.

Hiraki M, Kitajima Y, Sato S et al. Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer. World J Gastroenterol 2010; 16:330-8.

Hirankarn N, Avihingsanon Y, Wongpiyabovorn J. Genetic susceptibility to SLE is associated with TNF-alpha gene polymorphism -863, but not -308 and -238, in Thai population. Int J Immunogenet 2007; 34:425-30.

Hirankarn N, Tangwattanachuleeporn M, Wongpiyabovorn J, Wongchinsri J, Avihingsanon Y. Genetic association of interferon-alpha subtypes 1, 2 and 5 in systemic lupus erythematosus. Tissue Antigens 2008; 72:588-92.

Hirano A, Ikemura K, Takahashi M et al. Lack of correlation between UGT1A1*6, *28 genotypes, and plasma raltegravir concentrations in Japanese HIV-1-infected patients. AIDS Res Hum Retroviruses 2011. doi:10. 1089/AID. 2011. 0231.

Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 2005; 68:800-7.

Hirata H, Hinoda Y, Okayama N et al. CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 2008; 112:1964-73.

Hirata K, Takagi H, Yamamoto M et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 2008; 8:29-33.

Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994; 94:1662-7.

Hirata T, Okabe M, Kobayashi A, Ueda K, Matsuo M. Molecular mechanisms of subcellular localization of ABCG5 and ABCG8. Biosci Biotechnol Biochem 2009; 73:619-26.

Hirata-Koizumi M, Saito M, Miyake S, Hasegawa R. Incremental effect and mechanism of cyclosporine on blood concentration of statins and statin package insert information in Japan. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku 2005; 37-40.

Hiratsuka M. Development of simplified and rapid detection assay for genetic polymorphisms influencing drug response and its clinical applications. Yakugaku Zasshi 2002; 122:451-63.

Hiratsuka M, Hinai Y, Konno Y, Nozawa H, Konno S, Mizugaki M. Three novel single nucleotide polymorphisms (SNPs) of the CYP2B6 gene in Japanese individuals. Drug Metab Pharmacokinet 2004; 19:155-8.

Hiratsuka M, Hinai Y, Sasaki T et al. Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. Drug Metab Dispos 2007; 35:1730-2.

Hiratsuka M, Nozawa H, Konno Y, Saito T, Konno S, Mizugaki M. Human CYP4B1 gene in the japanese population analyzed by denaturing HPLC. Drug Metab Pharmacokinet 2004; 19:114-9.

Hirohata M, Ono K, Naiki H, Yamada M. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. Neuropharmacology 2005; 49:1088-99.

Hirohata M, Ono K, Yamada M. Non-steroidal anti-inflammatory drugs as anti-amyloidogenic compounds. Curr Pharm Des 2008; 14:3280-94.

Hiroi S, Harada H, Nishi H, Satoh M, Nagai R, Kimura A. Polymorphisms in the SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in Japanese. Biochem Biophys Res Commun 1999; 261:332-9.

Hiroi T, Chow T, Imaoka S, Funae Y. Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab Dispos 2002; 30:970-6.

Hiroi T, Imaoka S, Chow T, Yabusaki Y, Funae Y. Specific binding of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl propyl) piperazine (GBR-12935), an inhibitor of the dopamine transporter, to human CYP2D6. Biochem Pharmacol 1997; 53:1937-9.

Hiroi T, Ohishi N, Imaoka S, Yabusaki Y, Fukui H, Funae Y. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. J Pharmacol Exp Ther 1995; 272:939-44.

Hirono N, Hashimoto M, Yasuda M, Kazui H, Mori E. Accelerated memory decline in Alzheimer’s disease with apolipoprotein epsilon4 allele. J Neuropsychiatry Clin Neurosci 2003; 15:354-8.

Hirose T, Fujita K, Nishimura K et al. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer. Oncol Rep 2010; 24:529-36.

Hirota N, Ito K, Iwatsubo T et al. In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm Drug Dispos 2001; 22:53-71.

Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-80.

Hirota T, Ieiri I, Takane H et al. Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. Hum Mol Genet 2004; 13:2959-69.

Hirsch FR, Herbst RS, Olsen C et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008; 26:3351-7.

Hirsch-Reinshagen V, Zhou S, Burgess BL et al. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem 2004; 279:41197-207.

Hirt D, Treluyer JM, Jullien V et al. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women. Antimicrob Agents Chemother 2006; 50:2079-86.

Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6:1255-8.

Hisaka A, Kusama M, Ohno Y, Sugiyama Y, Suzuki H. A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling. Clin Pharmacokinet 2009; 48:653-66.

Hisamuddin IM, Yang VW. Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives. Pharmacogenomics 2007; 8:635-43.

Hiscox S, Barrett-Lee P, Borley AC, Nicholson RI. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss. Eur J Cancer 2010; 46:2187-95.

Hiuge-Shimizu A, Maeda N, Hirata A et al. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone. Arterioscler Thromb Vasc Biol 2011; 31:792-9.

Hivert MF, Manning AK, McAteer JB et al. Common variants in the adiponectin gene (ADIPOQ) associated with plasma adiponectin levels, type 2 diabetes, and diabetes-related quantitative traits: the Framingham Offspring Study. Diabetes 2008; 57:3353-9.

Hizaki K, Yamamoto H, Taniguchi H et al. Epigenetic inactivation of calcium-sensing receptor in colorectal carcinogenesis. Mod Pathol 2011; 24:876-84.

Hizawa N, Makita H, Nasuhara Y et al. Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest 2007; 132:1485-92.

Hlavata I, Vrana D, Smerhovsky Z et al. Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population. Oncol Rep 2010; 24:1347-53.

Ho BE, Shen DD, McCune JS et al. Effects of garlic on cytochromes P450 2C9- and 3A4-mediated drug metabolism in human hepatocytes. Sci Pharm 2010; 78:473-81.

Ho CK, Habib FK. Estrogen and androgen signaling in the pathogenesis of BPH. Nat Rev Urol 2011; 8:29-41.

Ho L, Qin W, Stetka BS, Pasinetti GM. Is there a future for cyclo-oxygenase inhibitors in Alzheimer’s disease? CNS Drugs 2006; 20:85-98

Ho MK, Mwenifumbo JC, Zhao B, Gillam EM, Tyndale RF. A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet Genomics 2008; 18:67-75.

Ho MK, Tyndale RF. Oerview of the pharmacogenomics of cigarette smoking. Pharmacogenomics J 2007; 7:81-98.

Ho MT, Kelly EJ, Bodor M, Bui T, Kowdley KV, Ho RJ. Novel cytochrome P450-2D6 promoter sequence variations in hepatitis C positive and negative subjects. Ann Hepatol 2011; 10:327-32.

Ho PC, Chalcroft SC, Coville PF, Wanwimolruk S. Grapefruit juice has no effect on quinine pharmacokinetics. Eur J Clin Pharmacol 1999; 55:393-8.

Ho PC, Saville DJ, Coville PF, Wanwimolruk S. Content of CYP3A4 inhibitors, naringin, naringenin and bergapten in grapefruit and grapefruit juice products. Pharm Acta Helv 2000; 74:379-85.

Ho PC, Saville DJ, Wanwimolruk S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 2001; 4:217-27.

Ho PY, Barton A, Worthington J et al. Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis 2008; 67:677-82.

Ho RH, Choi L, Lee W et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics 2007; 17:647-56.

Ho RH, Tirona RG, Leake BF et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006; 130:1793-806.

Ho SH, Singh M, Holloway AC, Crankshaw DJ. The effects of commercial preparations of herbal supplements commonly used by women on the biotransformation of fluorogenic substrates by human cytochromes P450. Phytother Res 2011. doi:10. 1002/ptr. 3371.

Ho SL, Kung MH, Li LS, Lauder IJ, Ramsden DB. Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson’s disease in Chinese and Caucasians. Eur J Neurol 1999; 6:323-9.

Ho SM. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004; 91:491-503.

Ho T, Vrabec JT, Burton AW. Hydrocodone use and sensorineural hearing loss. Pain Physician 2007; 10:467-72.

Ho WF, Koo SH, Yee JY, Lee JD. Genetic variations of the ABCC2 gene in the Chinese, Malay, and Indian populations of Singapore. Drug Metab Pharmacokinet 2008; 23:385-91.

Hobbs CA, James SJ, Parsian A et al. Congenital heart defects and genetic variants in the methylenetetrahydroflate reductase gene. J Med Genet 2006; 43:162-6.

Hobbs CA, Sherman SL, Yi P et al. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. Am J Hum Genet 2000; 67:623-30.

Hoblinger A, Grunhage F, Sauerbruch T, Lammert F. Association of the c. 3972C>T variant of the multidrug resistance-associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer. Digestion 2009; 80:36-9.

Hockly E, Richon V, Woodman B et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proc Nat Acad Sci USA 2003; 100:2041-6.

Hochberg Z, Chayen R, Reiss N et al. Clinical, biochemical, and genetic findings in a large pedigree of male and female patients with 5 alpha-reductase 2 deficiency. J Clin Endocrinol Metab 1996; 81:2821-7.

Hochepied T, Ameloot P, Brouckaert P, van Leuven F, Libert C. Differential response of a(2)-macroglobulin-deficient mice in models of lethal TNF-induced inflammation. Eur Cytokine Netw 2000; 11:597-601.

Hochhaus A, La Rosée P, Müller MC, Ernst T, Cross NC. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle 2011; 10:250-60.

Hochholzer W, Trenk D, Frundi D et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111:2560-4.

Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther 2000; 292:310-8.

Hochman JH, Chiba M, Yamazaki M, Tang C, Lin JH. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4. J Pharmacol Exp Ther 2001; 298:323-30.

Hodel EM, Ley SD, Qi W, Ariey F, Genton B, Beck HP. A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs. Malar J 2009; 8:285.

Hodgkinson CP, Ye S. Statins inhibit toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression. Pharmacogenet Genomics 2008; 18:803-13.

Hodgson E, Rose RL. Human metabolic interactions of environmental chemicals. J Biochem Mol Toxicol 2007; 21:182-6.

Hodgson E, Rose RL. Metabolic interactions of agrochemicals in humans. Pest Manag Sci 2008; 64:617-21.

Hodgson-Zingman DM, Karst ML, Zingman LV et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med 2008; 359:158-65.

Hodoglugil U, Williamson DW, Mahley RW. Polymorphisms in the hepatic lipase gene affect plasma HDL-cholesterol levels in a Turkish population. J Lipid Res 2010; 51:422-30.

Hodoğlugil U, Williamson DW, Yu Y, Farrer LA, Mahley RW. Glucuronic acid epimerase is associated with plasma triglyceride and high-density lipoprotein cholesterol levels in Turks. Ann Hum Genet 2011; 75:398-417.

Hoeft B, Linseisen J, Beckmann L et al. Polymorphisms in fatty-acid-metabolism-related genes are associated with colorectal cancer risk. Carcinogenesis 2010; 31:466-72.

Hoek JB, Cahill A, Pastorino JG. Alcohol and mitochondria: a dysfunctional relationship. Gastroenterology 2002; 122:2049-63.

Hoenig MR, Walker PJ, Gurnsey C, Beadle K, Johnson L. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J Clin Lipidol 2011; 5:91-6.

Hoet P, de Smedt E, Ferrari M et al. Evaluation of urinary biomarkers of exposure to benzene: correlation with blood benzene and influence of confounding factors. Int Arch Occup Environ Health 2009; 82:985-95.

Hofer S, Frei K, Rutz HP. Gefitinib accumulation in glioblastoma tissue. Cancer Biol Ther 2006; 5:483-4.

Hoffman SMG, Nelson DR, Keeney DS. Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 2001; 11:687-98.

Hoffmann AC, Wild P, Leicht C et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010; 12:628-36.

Hoffmann S, Cepok S, Grummel V et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008; 83:219-27.

Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-8.

Hofker M, Wijmenga C. A supersized list of obesity genes. Nat Genet 2009; 41:139-40.

Hofmann Bowman MA, Gawdzik J, Bukhari U et al. S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol 2011; 31:337-44.

Hofmann JN, Keifer MC, Furlong CE et al. Serum cholinesterase inhibition in relation to paraoxonase-1 (PON1) status among organophosphate-exposed agricultural pesticide handlers. Environ Health Perspect 2009; 117:1402-8.

Hofmann MH, Blievernicht JK, Klein K et al. Aberrant splicing caused by single nucleotide polymorphism c. 516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 2008; 325:284-92.

Hoft NR, Stitzel JA, Hutchison KE, Ehringer MA. CHRNB2 promoter region: association with subjective effects to nicotine and gene expression differences. Genes Brain Behav 2011; 10:176-85.

Hogan DB, Goldlist B, Naglie G, Patterson C. Comparison studies of cholinesterase inhibitors for Alzheimer’s disease. Lancet Neurol 2004; 3:622-8.

Hogan KJ, Burmester JK, Caldwell MD et al. Perioperative genomic profiles using structure-specific oligonucleotide probes. Clin Med Res 2009; 7:69-84.

Hogg M, Grujic ZM, Baker M et al. The L266V tau mutation is associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy. Acta Neuropathol 2003; 106:323-36.

Hohoff C, Mullings EL, Heatherley SV et al. Adenosine A(2A) receptor gene: Evidence for association of risk variants with panic disorder and anxious personality. J Psychiatr Res 2010; 44:930-7.

Hoit BD, Suresh DP, Craft L, Walsh RA, Liggett SB. beta2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am Heart J 2000; 139:537-42.

Hokkanen J, Tolonen A, Mattila S, Turpeinen M. Metabolism of hyperforin, the active constituent of St. John’s wort, in human liver microsomes. Eur J Pharm Sci 2011; 42:273-84.

Holcomb L, Gordon MN, McGowan E et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998; 4:97-100.

Holmstock N, Mols R, Annaert P, Augustijns P. In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption. Drug Metab Dispos 2010; 38:1407-10.

Holownia A, Braszko JJ. Tamoxifen cytotoxicity in hepatoblastoma cells stably transfected with human CYP3A4. Biochem Pharmacol 2004; 67:1057-64.

Holownia A, Cederbaum AI. Threshold for antiproliferative and proapoptotic activity of ttaxol in HepG2 cells expressing human CYP3A4: effect of P-glycoprotein transporters. Pharmacology 2003; 69:142-9.

Holst F, Stahl PR, Ruiz C et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007; 39:655-60.

Holstein A, Hahn M, Patzer O, Seeringer A, Kovacs P, Stingl J. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur J Clin Pharmacol 2011; 67:471-6.

Holsworth DD, Cai C, Cheng XM et al. Ketopiperazine-based renin inhibitors: optimization of the “C” ring. Bioorg Med Chem Lett 2006; 16:2500-4.

Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990; 46:428-33.

Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2009; 18:1929-33.

Holthe M, Rakvåg TN, Klepstad P et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 2003; 3:17-26.

Holtman L, van Vliet EA, Edelbroek PM, Aronica E, Gorter JA. Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy. Epilepsy Res 2010; 91:49-56.

Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006; 26:1601-7.

Holtzman DM, Bales KR, Tenkova T et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Nat Acad Sci USA 2000; 97:2892-7.

Holtzman DM, Bales KR, Wu S et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer’s disease. J Clin Invest 1999; 103:15-21.

Holzhäuser E, Albrecht C, Zhou Q et al. Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities. J Cardiovasc Pharmacol 2011; 57:447-54.

Holzman PS. Eye movements and the search for the essence of schizophrenia. Brain Res Rev 2000; 31:350-6.

Holland KD, Kearney JA, Glauser TA et al. Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy. Neurosci Lett 2008; 433:65-70.

Holland ML, Allen JD, Arnold JC. Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol 2008; 591:128-31.

Hollopeter G, Jantzen HM, Vincent D et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409:202-7.

Holloway JW, Barton SJ, Holgate ST, Rose-Zerilli MJ, Sayers I. The role of LTA4H and ALOX5AP polymorphism in asthma and allergy susceptibility. Allergy 2008; 63:1046-53.

Holloway JW, Yang IA, Ye S. Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet Genomics 2005; 15:15-21.

Höllt V. A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans. Pharmacogenetics 2002; 12:1-2.

Hom G, Graham RR, Modrek B et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008; 358:900-9.

Homann N, König IR, Marks M et al. Alcohol and colorectal cancer: the role of alcohol dehydrogenase 1C polymorphism. Alcohol Clin Exp Res 2009; 33:551-6.

Homann N, Stickel F, König IR et al. Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int J Cancer 2006; 118:1998-2002.

Homma M, Beckerman K, Hayashi S et al. Liquid chromatographic determination of urinary 6beta-hydroxycortisol to assess cytochrome p-450 3A activity in HIV positive pregnant women. J Pharm Biomed Anal 2000; 23:629-35.

Homolya L, Orbán TI, Csanády L, Sarkadi B. Mitoxantrone is expelled by the ABCG2 multidrug transporter directly from the plasma membrane. Biochim Biophys Acta 2011; 1808:154-63.

Honda A, Miyazaki T, Ikegami T et al. Cholesterol 25-hydroxylation activity of CYP3A. J Lipid Res 2011; 52:1509-16.

Honda A, Salen G, Matsuzaki Y et al. Side chain hydroxylations in bile acid biosynthesis catalyzed by CYP3A are markedly up-regulated in Cyp27-/- mice but not in cerebrotendinous xanthomatosis. J Biol Chem 2001; 276:34579-85.

Honda H, Tomizawa M, Casida JE. Neo-nicotinoid metabolic activation and inactivation established with coupled nicotinic receptor-CYP3A4 and -aldehyde oxidase systems. Toxicol Lett 2006; 161:108-14.

Honda M, Muroi Y, Tamaki Y et al. Functional characterization of CYP2B6 allelic variants in demethylation of anti-malarial artemether. Drug Metab Dispos 2011; 39:1860-5.

Honda M, Nozawa T, Igarashi N et al. Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers. Biol Pharm Bull 2005; 28:1476-9.

Honda M, Ogura Y, Toyoda W et al. Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers. Biol Pharm Bull 2006; 29:772-8.

Honetschlägerová Z, Sporková A, Kopkan L et al. Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. J Hypertens 2011; 29:1590-601.

Hong C, Walczak R, Dhamko H et al. Constitutive activation of LXR in macrophages regulates metabolic and inflammatory gene expression: identification of ARL7 as a direct target. J Lipid Res 2011; 52:531-9.

Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 2006; 6:27-33.

Hong CJ, Liou YJ, Bai YM, Chen TT, Wang YC, Tsai SJ. Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics 2010; 20:359-66.

Hong H, Su H, Ma L et al. In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor. Drug Metab Dispos 2011; 39:1658-67.

Hong IH, Ji H, Hwa SY et al. The protective effect of ENA actimineral resource A on CCl4-induced liver injury in rats. Mar Biotechnol 2011; 13:462-73.

Hong KH, Lee YJ, Lee E et al. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation 2008; 118:722-30.

Hong L, Han Y, Zhang H et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010; 251:1056-63.

Hong SH, Rhyne J, Zeller K, Miller M. Novel ABCA1 compound variant associated with HDL cholesterol deficiency. Biochim Biophys Acta 2002; 1587:60-4.

Hong SP, Yang JS, Han JY et al. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. J Pharm Pharmacol 2011; 63:129-35.

Hong X, Xing H, Yu Y et al. Genetic polymorphisms of the urea transporter gene are associated with antihypertensive response to nifedipine GITS. Methods Find Exp Clin Pharmacol 2007; 29:3-10.

Hong X, Zhang S, Mao G et al. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol 2005; 61:627-34.

Hong Y, Ho KS, Eu KW, Cheah PY. A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis. Clin Cancer Res 2007; 13:1107-14.

Hong YB, Kang HJ, Kwon SY et al. Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells. Pancreas 2010; 39:463-72.

Hong YJ, Yoon B, Shim YS et al. APOE ε4 allele status in Korean dementia patients with severe white matter hyperintensities. J Alzheimers Dis 2011; 24:519-24.

Hong ZF, Li TJ, Zhao JY. Effect of total alkaloids of Rubus alceaefolius poiron on gene expressions of CYP2E1 and CYP3A1 in rats with acute liver injury. Zhongguo Zhong Xi Yi Jie He Za Zhi 2009; 29:711-5.

Hongo I, Bloch KC. Ehrlichia infection of the central nervous system. Curr Treat Options Neurol 2006; 8:179-84.

Honjo H, Iwasa K, Kawata M et al. Progestins and estrogens and Alzheimer’s disease. J Steroid Biochem Mol Biol 2005; 93:305-8.

Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. Clin Pharmacol Ther 2011; 89:579-86.

Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metab Dispos 2011; 39:1977-86.

Honorat M, Falson P, Terreux R, di Pietro A, Dumontet C, Payen L. Multidrug resistance ABC transporter structure predictions by homology modeling approaches. Curr Drug Metab 2011; 12:268-77.

Honorat M, Mesnier A, Di Pietro A et al. Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. Biochem Biophys Res Commun 2008; 375:308-14.

Höög JO, Hedén LO, Larsson K, Jörnvall H, von Bahr-Lindström H. The gamma 1 and gamma 2 subunits of human liver alcohol dehydrogenase. cDNA structures, two amino acid replacements, and compatibility with changes in the enzymatic properties. Eur J Biochem 1986; 159:215-8.

Hoogeveen A, Willemsen R, Meyer N et al. Characterization and localization of the Huntington’s disease gene products. Hum Molec Genet 1993; 2:2069-73.

Hooijberg JH, Broxterman HJ, Kool M et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999; 59:2532-5.

Hooijberg JH, de Vries NA, Kaspers GJ, Pieters R, Jansen G, Peters GJ. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemother Pharmacol 2006; 58:1-12.

Hooker AC, Ten Tije AJ, Carducci MA et al. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin Pharmacol Ther 2008; 84:111-8.

Hoover CA, Carmichael JK, Nolan PE Jr, Marcus FI. Cardiac Arrest Associated With Combination Cisapride and Itraconazole Therapy. J Cardiovasc Pharmacol Ther 1996; 1:255-8.

Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P. Cyclooxygenase-1 and -2 in the different stages of Alzheimer’s disease pathology. Curr Pharm Des 2008; 14:1419-27.

Hope C, Chu CT, DeKosky ST, Gonias SL, Kamboh MI, Mettenburg J. Functional analysis of plasma α2-macroglobulin from Alzheimer’s disease patients with the A2M intronic deletion. Neurobiology of Disease 2003; 14:504-512.

Hopkins PC, Sáinz-Fuertes R, Lovestone S. The impact of a novel Apolipoprotein E and Amyloid-β protein precursor-interacting protein on the production of Amyloid-β. J Alzheimers Dis 2011; 26:239-53.

Hopkins PN, Hunt SC, Jeunemaitre X et al. Angiotensinogen genotype affects renal and adrenal responses to angiotensin II in essential hypertension. Circulation 2002; 105:1921-7.

Hopkins S, Scorneaux B, Huang Z et al. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother 2010; 54:660-72.

Hoppe B. Evidence of true genotype-phenotype correlation in primary hyperoxaluria type 1. Kidney Int 2010; 77:383-5.

Hor SY, Lee SC, Wong CI et al. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J 2008; 8:139-46.

Horáková D, Kýr M, Havrdová E et al. Apolipoprotein E ε4-Positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: a 15-year disease history model based on a 4-year longitudinal study. Folia Biol 2010; 56:242-51.

Hori M, Oniki K, Ueda K et al. Combined glutathione S-transferase T1 and M1 positive genotypes afford protection against type 2 diabetes in Japanese. Pharmacogenomics 2007; 8:1307-14.

Hori N, Hayashi H, Sugiyama Y. Calpain-mediated cleavage negatively regulates the expression level of ABCG1. Atherosclerosis 2011; 215:383-91.

Horibata K, Iwamoto Y, Kuraoka I et al. Complete absence of Cockayne syndrome group B gene product gives rise to UV-sensitive syndrome but not Cockayne syndrome. Proc Natl Acad Sci USA 2004; 101:15410-5.

Horibe S, Nagai J, Yumoto R, Tawa R, Takano M. Accumulation and photodynamic activity of chlorin e6 in cisplatin-resistant human lung cancer cells. J Pharm Sci 2011; 100:3010-7.

Horie T, Ono K, Horiguchi M et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA 2010; 107:17321-6.

Horiguchi T, Uryu K, Giasson BI et al. Nitration of tau protein is linked to neurodegeneration in tauopathies. Am J Pathol 2003; 163:1021-31.

Horikawa M, Kato Y, Tyson CA, Sugiyama Y. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet 2002; 17:23-33.

Horikiri Y, Suzuki T, Mizobe M. Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci 1998; 87:289-94.

Horikiri Y, Suzuki T, Mizobe M. Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci 1998; 63:1097-108.

Horinouchi T, Morishima S, Tanaka T et al. Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci 2007; 81:399-404.

Horiuchi I, Nozawa T, Fujii N et al. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure. Biol Pharm Bull 2008; 31:976-80.

Horn J, Milewska M, Arnold SM, Leggas M. Metabolic pathways of the camptothecin analog AR-67. Drug Metab Dispos 2011; 39:683-92.

Horsfall LJ, Zeitlyn D, Tarekegn A et al. Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations. Ann Hum Genet 2011; 75:236-46.

Horstmann S, Lucae S, Menke A et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2010; 35:727-40.

Horton T, Graham B, Corral-Debrinsky M et al. Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington’s disease patients. Neurology 1995; 45:1879-83.

Horvath GA, Stockler-Ipsiroglu SG, Salvarinova-Zivkovic R et al. Autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia: evidence of a phenotypic continuum between dominant and recessive forms. Mol Genet Metab 2008; 94:127-31.

Horvath T, Madi BC, Iuppa IM, Kennedy GE, Rutherford G, Read JS. Interventions for preventing late postnatal mother-to-child transmission of HIV. Cochrane Database Syst Rev 2009; CD006734.

Horwedel C, Tsogoeva SB, Wei S, Efferth T. Cytotoxicity of artesunic acid homo-and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells. J Med Chem 2010; 53:4842-8.

Horwich AL, Weissman JS. Deadly conformations-protein misfolding in prion disease. Cell 1997; 89:499-510.

Hosagrahara VP, Hansen LK, Remmel RP. Induction of the metabolism of midazolam by rifampin in cultured porcine hepatocytes: preliminary evidence for CYP3A isoforms in pigs. Drug Metab Dispos 1999; 27:1512-8.

Hosaka T, Sekimoto M, Nemoto K, Degawa M. Augmentation of 3-methylcholanthrene-induced bioactivation in the human hepatoma cell line HepG2 by the calcium channel blocker nicardipine. Cancer Sci 2010; 101:652-7.

Hosek J, Bartosová L, Gregor P et al. Frequency of representative single nucleotide polymorphisms associated with inflammatory bowel disease in the Czech Republic and Slovak Republic. Folia Biol 2008; 54:88-96.

Hosgood HD 3rd, Purdue MP, Wang SS et al. A pooled analysis of three studies evaluating genetic variation in innate immunity genes and non-Hodgkin lymphoma risk. Br J Haematol 2011; 152:721-6.

Hoshino J, Park EJ, Kondratyuk TP et al. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem 2010; 53:5033-43.

Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009; 9:576-86.

Hoskins JM, Marcuello E, Altes A et al. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res 2008; 14:1788-96.

Hosohata K, Masuda S, Yonezawa A et al. MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. Pharm Res 2009; 26:1590-5.

Hosomi H, Akai S, Minami K et al. An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells. Toxicol In Vitro 2010; 24:1032-8.

Hosomi R, Fukunaga K, Arai H, Nishiyama T, Yoshida M. Effects of dietary fish protein on serum and liver lipid concentrations in rats and the expression of hepatic genes involved in lipid metabolism. J Agric Food Chem 2009; 57:9256-62.

Hosono-Fukao T, Hosono T, Seki T, Ariga T. Diallyl trisulfide protects rats from carbon tetrachloride-induced liver injury. J Nutr 2009; 139:2252-6.

Hossain M, Wright E, Baweja R, Ludden T, Miller R. Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. Pharm Res 1997; 14:309-15.

Hossain MA, Tsujita M, Akita N, Kobayashi F, Yokoyama S. Cholesterol homeostasis in ABCA1/LCAT double-deficient mouse. Biochim Biophys Acta 2009; 1791:1197-205.

Hosseinpour F, Ellfolk M, Norlin M, Wikvall K. Phenobarbital suppresses vitamin D3 25-hydroxylase expression: a potential new mechanism for drug-induced osteomalacia. Biochem Biophys Res Commun 2007; 357:603-7.

Hosten B, Abbara C, Cibert M et al. Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice. Anticancer Drugs 2010; 21:193-201.

Hostler D, Zhou J, Tortorici MA et al. Mild hypothermia alters midazolam pharmacokinetics in normal healthy volunteers. Drug Metab Dispos 2010; 38:781-8.

Hou XL, Takahashi K, Kinoshita N et al. Possible inhibitory mechanism of Curcuma drugs on CYP3A4 in 1alpha,25 dihydroxyvitamin D3 treated Caco-2 cells. Int J Pharm 2007; 337:169-77.

Houlden H, Crook R, Backhovens H et al. ApoE genotype is a risk factor in nonpresinilin early-onset Alzheimer’s disease families. Am J Med Genet 1998; 81:117-21.

Houlle S, Charbonnier F, Houivet E et al. Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers. Eur J Hum Genet 2011; 19:887-92.

Houston JB, Galetin A. Modelling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 2005; 433:351-60.

Howard CB, Stevens J, Izevbigie EB, Walker A, McDaniel O. Time and dose-dependent modulation of phase 1 and phase 2 gene expression in response to treatment of MCF-7 cells with a natural anti-cancer agent. Cell Mol Biol 2003; 49:1057-65.

Howard CG, Mullins JJ, Mitchell KD. Direct renin inhibition with aliskiren normalizes blood pressure in Cyp1a1-Ren2 transgenic rats with inducible angiotensin II-dependent malignant hypertension. Am J Med Sci 2011; 341:383-7.

Howard R, Dennehey J, Lovestone S et al. Apolipoprotein e genotype and late paraphrenia. Int J Geriat Psychiatry 1995; 10:147-50.

Howard TD, Hsu FC, Grzywacz JG et al. Evaluation of candidate genes for cholinesterase activity in farmworkers exposed to organophosphorus pesticides: association of single nucleotide polymorphisms in BCHE. Environ Health Perspect 2010; 118:1395-9.

Howe K, Gibson GG, Coleman T, Plant N. In silico and in vitro modeling of hepatocyte drug transport processes: importance of ABCC2 expression levels in the disposition of carboxydichlorofluroscein. Drug Metab Dispos 2009; 37:391-9.

Howe LR, Brown PH. Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res 2011; 4:1149-57.

Howell JE, Szabatura AH, Hatfield Seung A, Nesbit SA. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. J Oncol Pharm Pract 2008; 14:157-62.

Howell WM, Calder PC, Grimble RF. Gene polymorphisms, inflammatory diseases and cancer. Proc Nutr Soc 2002; 61:447-56.

Howes MJ, Perry E. The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging 2011; 28:439-68.

Howson JM, Walker NM, Clayton D, Todd JA; Type 1 Diabetes Genetics Consortium. Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A. Diabetes Obes Metab 2009; 11 Suppl 1:31-45.

Hoyo-Vadillo C, Venturelli CR, González H et al. Metabolism of omeprazole after two oral doses in children 1 to 9 months old. Proc West Pharmacol Soc 2005; 48:108-9.

Hoyumpa AM Jr. Alcohol interactions with benzodiazepines and cocaine. Adv Alcohol Subst Abuse 1984; 3:21-34.

Hradsky O, Dusatkova P, Lenicek M et al. The CTLA4 variants may interact with the IL23R- and NOD2-conferred risk in development of Crohn’s disease. BMC Med Genet 2010; 11:91.

Hrubá E, Trilecová L, Marvanová S et al. Genotoxic polycyclic aromatic hydrocarbons fail to induce the p53-dependent DNA damage response, apoptosis or cell-cycle arrest in human prostate carcinoma LNCaP cells. Toxicol Lett 2010; 197:227-35.

Hsiao DJ, Wu LS, Huang SY, Lin E. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. Pharmacogenet Genomics 2009; 19:730-3.

Hsiao K, Baker HF, Crow TJ et al. Linkage of a prion protein missense variant to Gerstmann-Straussler syndrome. Nature 1989; 338:342-5.

Hsiao K, Chapman P, Nilsen S et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274:99.

Hsiao K, Dlouhly SR, Farlow MR et al. Mutant prion proteins in Gerstmann. Straussler-Scheinker disease with neurofibrillary tangles. Nat Genet 1992; 1:68-71.

Hsiao PJ, Lu MY, Chiang FY, Shin SJ, Tai YD, Juo SH. Vascular endothelial growth factor gene polymorphisms in thyroid cancer. J Endocrinol 2007; 2:265-70.

Hsieh KP, Lin YY, Cheng CL et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 2001; 29:268-73.

Hsieh MC, Lin KD, Tien KJ et al. Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism 2010; 59:1139-44.

Hsieh YH, Chou CY. Structural and functional characterization of human apolipoprotein E 72-166 peptides in both aqueous and lipid environments. J Biomed Sci 2011; 18:4.

Hsieh YY, Lin YJ, Chang CC et al. Human lymphocyte antigen B-associated transcript 2, 3, and 5 polymorphisms and haplotypes are associated with susceptibility of Kawasaki disease and coronary artery aneurysm. J Clin Lab Anal 2010; 24:262-8.

Hsiu SL, Hou YC, Wang YH, Tsao CW, Su SF, Chao PD. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci 2002; 72:227-35.

Hsiung CA, Lan Q, Hong YC et al. The 5p15. 33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet 2010. doi:10. 1371/journal. pgen. 1001051.

Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35:275-91.

Hsu CC, Bray MS, Kao WH, Pankow JS, Boerwinkle E, Coresh J. Genetic variation of the renin-angiotensin system and chronic kidney disease progression in black individuals in the atherosclerosis risk in communities study. J Am Soc Nephrol 2006; 17:504-12.

Hsu CM, Hsu YA, Tsai Y et al. Emodin inhibits the growth of hepatoma cells: finding the common anti-cancer pathway using Huh7, Hep3B, and HepG2 cells. Biochem Biophys Res Commun 2010; 392:473-8.

Hsu ES. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics. Am J Ther 2010; 17:476-86.

Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995; 9:743-59.

Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350:427-8.

Hsu LA, Chang CJ, Wu S et al. Association between functional variants of the ICAM1 and CRP genes and metabolic syndrome in Taiwanese subjects. Metabolism 2010; 59:1710-6.

Hsu LC, Chang WC, Yoshida A. Genomic structure of the human cytosolic aldehyde dehydrogenase gene. Genomics 1989; 5:857-65.

Hsu MH, Savas U, Griffin KJ, Johnson EF. Regulation of human cytochrome P450 4F2 expression by sterol regulatory element-binding protein and lovastatin. J Biol Chem 2007; 282:5225-36.

Hsu MH, Savas U, Lasker JM, Johnson EF. Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside induce cytochrome P450 4F2 expression through an AMP-activated protein kinase-dependent pathway. J Pharmacol Exp Ther 2011; 337:125-36.

Hsu WC, Chen WH, Chang MT, Chiu HC. Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin. Clin Neuropharmacol 2002; 25:266-8.

Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45:3445-50.

Hu B, Unwalla RJ, Goljer I et al. Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist. J Med Chem 2010; 53:3296-304.

Hu BC, Li Y, Li FH et al. Peripheral and central augmentation indexes in relation to the CYP4F2 polymorphisms in Chinese. J Hypertens 2011; 29:501-8.

Hu C, Diévart A, Lupien M, Calvo E, Tremblay G, Jolicoeur P. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Am J Pathol 2006; 168:973-90.

Hu C, Wei H, van den Hoek AM et al. Plasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden. CETP transgenic mice. PLoS One 2011. doi:10. 1371/journal. pone. 0019423.

Hu C, Xu D, Du W et al. Novel 4 beta-anilino-podophyllotoxin derivatives: design synthesis and biological evaluation as potent DNA-topoisomerase II poisons and anti-MDR agents. Mol Biosyst 2010; 6:410-20.

Hu D, Serrano F, Oury TD, Klann E. Aging-dependent alterations in synaptic plasticity and memory in mice that overexpress extracellular superoxide dismutase. J Neurosci 2006; 26:3933-41.

Hu G, Johnson EF, Kemper B. CYP2C8 exists as a dimer in natural membranes. Drug Metab Dispos 2010; 38:1976-83.

Hu H, Jui HY, Hu FC, Chen YH, Lai LP, Lee CM. Predictors of therapeutic response to beta-blockers in patients with heart failure in Taiwan. J Formos Med Assoc 2007; 106:641-8.

Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A-beta); retards A-beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 2001; 276:47863-8.

Hu J, Iyer-Biswas S, Sealfon SC, Wetmur J, Jayaprakash C, Hayot F. Power-laws in interferon-B mRNA distribution in virus-infected dendritic cells. Biophys J 2009; 97:1984-9.

Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 2010; 102:1276-83.

Hu L, Xu W, Zhang X et al. In-vitro and in-vivo evaluations of cytochrome P450 1A2 interactions with nuciferine. J Pharm Pharmacol 2010; 62:658-62.

Hu M, Li Y, Davitt CM et al. Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase. Pharm Res 1999; 16:1352-9.

Hu M, To KK, Mak VW, Tomlinson B. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin Drug Metab Toxicol 2011; 7:49-62.

Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag 2008; 4:1209-20.

Hu MG, Deshpande A, Enos M et al. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res 2009; 69:810-8.

Hu Q, Jagusch C, Hille UE, Haupenthal J, Hartmann RW. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer. J Med Chem 2010; 53:5749-58.

Hu S, Boettcher BR, Dunning BE. The mechanisms underlying the unique pharmacodynamics of nateglinide. Diabetologia 2003; 46 Suppl 1:37-43.

Hu S, Chen Z, Franke R et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009; 15:6062-9.

Hu S, Shen G, Zhao W, Wang F, Jiang X, Huang D. Paeonol, the main active principles of Paeonia moutan, ameliorates alcoholic steatohepatitis in mice. J Ethnopharmacol 2010; 128:100-6.

Hu SP, Zhou GB, Luan JA et al. Polymorphisms of HLA-A and HLA-B genes in genetic susceptibility to esophageal carcinoma in Chaoshan Han Chinese. Dis Esophagus 2010; 23:46-52.

Hu W, Liu W. Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population. In Vitro Cell Dev Biol Anim 2010; 46:497-501.

Hu W, Yang H, Sun J et al. Polymorphisms in CYP1B1 modify the risk of idiopathic male infertility with abnormal semen quality. Clin Chim Acta 2011; 412:1778-82.

Hu X, Pickering E, Liu YC et al. Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer’s disease. PLoS One 2011. doi:10. 1371/journal. pone. 0016616.

Hu X, Zhang Z, Ma D et al. TP53, MDM2, NQO1, and susceptibility to cervical cancer. Cancer Epidemiol Biomarkers Prev 2010; 19:755-61.

Hu Y, Hakkola J, Oscarson M, Ingelman-Sundberg M. Structural and functional characterization of the 5’-flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene. Biochem Biophys Res Commun 1999; 263:286-93.

Hu Y, Kupfer D. Metabolism of the endocrine disruptor pesticide-methoxychlor by human P450s: pathways involving a novel catechol metabolite. Drug Metab Dispos 2002; 30:1035-42.

Hu Y, Liu Y, Pelletier S et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 36:453-61.

Hu Y, Oscarson M, Johansson I et al. Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol Pharmacol 1997; 51:370-6.

Hu Y, Sampson KE, Heyde BR et al. Saturation of multidrug-resistant protein 2 (mrp2/abcc2)-mediated hepatobiliary secretion: nonlinear pharmacokinetics of a heterocyclic compound in rats after intravenous bolus administration. Drug Metab Dispos 2009; 37:841-6.

Hu Y, Sampson KE, Xing L et al. Two branched polar groups and polar linker moieties of thiophene amide derivatives are essential for MRP2/ABCC2 recognition. Drug Metab Lett 2010; 4:254-61.

Hu Y, Yang S, Shilliday FB et al. Novel metabolic bioactivation mechanism for a series of anti-inflammatory agents (2,5-diaminothiophene derivatives) mediated by cytochrome p450 enzymes. Drug Metab Dispos 2010; 38:1522-31.

Hu YF, He J, Chen GL et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 2005; 353:187-92.

Hu YF, Qiu W, Liu ZQ et al. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol 2006; 33:1093-8.

Hu YF, Tu JH, Tan ZR et al. Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica 2007; 37:315-27.

Hu YP, Robert J. Azelastine and flezelastine as reversing agents of multidrug resistance: pharmacological and molecular studies. Biochem Pharmacol 1995; 50:169-75.

Hu YS, Pan Y, Li WH, Zhang Y, Li J, Ma BA. Association between TGFBR1*6A and osteosarcoma: a Chinese case-control study. BMC Cancer 2010; 10:169.

Hu YW, Wang Q, Ma X et al. TGF-beta1 up-regulates expression of ABCA1, ABCG1 and SR-BI through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells. J Atheroscler Thromb 2010; 17:493-502.

Hu Z, Yang X, Ho PC et al. Herb-drug interactions: a literature review. Drugs 2005; 65:1239-82.

Hua CX, Li YS, Liu YQ et al. Rapid response to lipids profile and leukocyte gene expression after rosuvastatin administration in Chinese healthy volunteers. Chin Med J 2008; 121:1215-9.

Hua Q, He RQ. Tau could protect DNA double helix structure. Biochim Biophys Acta 2003; 1645:205-11.

Huang AQ, Hu YH, Zhan SY et al. Lipoprotein lipase gene S447X polymorphism modulates the relation between central obesity and serum lipids, a twin study. Int J Obes 2006; 30:1693-701.

Huang BS, Leenen FH. Mineralocorticoid actions in the brain and hypertension. Curr Hypertens Rep 2011; 13:214-20.

Huang BS, Zheng H, Tan J, Patel KP, Leenen FH. Regulation of hypothalamic renin-angiotensin system and oxidative stress by aldosterone. Exp Physiol 2011; 96:1028-38.

Huang CS. Molecular genetics of unconjugated hyperbilirubinemia in Taiwanese. J Biomed Sci 2005; 12:445-50.

Huang CS, Luo GA, Huang MJ, Chen ES, Young TH, Chao YC. A novel compound heterozygous variation of the uridine-diphosphoglucuronosyl transferase 1A1 gene that causes Crigler-Najjar syndrome type II. Pharmacogenetics 2001; 11:639-42.

Huang CS, Luo GA, Huang ML, Yu SC, Yang SS. Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese. Pharmacogenetics 2000; 10:539-44.

Huang CW, Lai ML, Lin MS, Lee HL, Huang JD. Dose-response relationships of propranolol in Chinese subjects with different CYP2D6 genotypes. J Chin Med Assoc 2003; 66:57-62.

Huang D, Fu ZY, Yang YN, Xie X, Wang YH, Ma YT. Association on the haplotypes of CYP4F2 gene and myocardial infarction. Zhonghua Liu Xing Bing Xue Za Zhi 2009; 30:733-6.

Huang G, Xing H, Hao K et al. Beta2 adrenergic receptor gene Arg16Gly polymorphism is associated with therapeutic efficacy of benazepril on essential hypertension in Chinese. Clin Exp Hypertens 2004; 26:581-92.

Huang H, Chang HH, Xu Y et al. Epoxyeicosatrienoic acid inhibition alters renal hemodynamics during pregnancy. Exp Biol Med 2006; 231:1744-52.

Huang H, Wang H, Sinz M et al. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 2007; 26:258-68.

Huang HD, Lin FJ, Li XJ, Wang LR, Jiang GR. Genetic polymorphisms of the renin-angiotensin-aldosterone system in Chinese patients with end-stage renal disease secondary to IgA nephropathy. Chin Med J 2010; 123:3238-42.

Huang HL, Xu JN, Wang QK et al. Association between polymorphisms of XPD gene and susceptibility to chronic benzene poisoning. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2006; 24:390-3.

Huang IP, Sun SP, Cheng SH et al. Enhanced chemotherapy of cancer using pH-sensitive Mesoporous Silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance. Mol Cancer Ther 2011; 10:761-9.

Huang J, Si L, Jiang L, Fan Z, Qiu J, Li G. Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. Int J Pharm 2008; 356:351-3.

Huang JN, Koerper MA. Factor V deficiency: a concise review. Haemophilia 2008; 14:1164-9.

Huang LM, Zhao JH, Wang GC, Zhou JP. Recent advance in the mechanism study of polymeric inhibitors of P-glycoprotein. Yao Xue Xue Bao 2010; 45:1224-31.

Huang ML, van Peer A, Woestenborghs R et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54:257-68.

Huang MY, Fang WY, Lee SC, Cheng TL, Wang JY, Lin SR. ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. BMC Cancer 2008; 8:50.

Huang NF, Kurpinski K, Fang Q, Lee RJ, Li S. Proteomic identification of biomarkers of vascular injury. Am J Transl Res 2011; 3:139-48.

Huang Q, Szklarz GD. Significant increase in phenacetin oxidation on L382V substitution in human cytochrome P450 1A2. Drug Metab Dispos 2010; 38:1039-45.

Huang R, Murry DJ, Kolwankar D, Hall SD, Foster DR. Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol 2006; 71:1695-704.

Huang R, Vider J, Serganova I, Blasberg RG. ATP-Binding cassette transporters modulate both coelenterazine- and d-luciferin-based bioluminescence imaging. Mol Imaging 2011; 10:215-26.

Huang RS, Duan S, Bleibel WK et al. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci USA 2007; 104:9758-63.

Huang RS, Duan S, Kistner EO et al. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res 2008; 68:3161-8.

Huang RS, Duan S, Kistner EO, Hartford CM, Dolan ME. Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther 2008; 7:3038-46.

Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009; 59:42-55.

Huang S, Chen B, Xiang D, Huang L, An B, Li G. Association between apolipoprotein E gene polymorphism and the dose for warfarin maintenance. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2011; 36:212-6.

Huang SC, Koch CA, Vortmeyer AO et al. Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. Cancer Res 2000; 60:6223-6.

Huang SC, Torres-Cruz J, Pack SD et al. Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma. J Clin Endocr Metab 2003; 88:459-63.

Huang SW, Chen HS, Wang XQ et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 2009; 19:226-34.

Huang SW, Xiang DK, Huang L, Chen BL, An BQ, Li GF, Luo ZY. Influence of GGCX genotype on warfarin dose requirements in Chinese patients. Thromb Res 2011; 127:131-4.

Huang T, Fang ZZ, Zhang YY etal. Inhibitory potential of chlormadinone acetate (CMA) on five important UDP-glucuronosyltransferases in human liver. Pharmazie 2011; 66:212-5.

Huang W, Bansode RR, Xie Y et al. Disruption of the murine protein kinase Cbeta gene promotes gallstone formation and alters biliary lipid and hepatic cholesterol metabolism. J Biol Chem 2011; 286:22795-805.

Huang W, Gallois Y, Bouby N et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA 2001; 98:13330-4.

Huang W, Lin YS, McConn DJ 2nd et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 2004; 32:1434-45.

Huang W, Ma JZ, Payne TJ, Beuten J, Dupont RT, Li MD. Significant association of DRD1 with nicotine dependence. Hum Genet 2008; 123:133-40.

Huang W, Moriyama K, Koga T et al. Novel mutations in ABCA1 gene in Japanese patients with Tangier disease and familial high density lipoprotein deficiency with coronary heart disease. Biochim Biophys Acta 2001; 1537:71-8.

Huang W, Payne TJ, Ma JZ, Li MD. A functional polymorphism, rs6280, in DRD3 is significantly associated with nicotine dependence in European-American smokers. Am J Med Genet B Neuropsychiatr Genet 2008; 147:1109-15.

Huang WC, Chen YJ, Li LY et al. Nuclear translocation of EGFR by AKT-dependent phosphorylation enhances BCRP/ABCG2 expression in gefitinib-resistant cells. J Biol Chem 2011; 286:20558-68.

Huang WH, Sheng R, Hu YZ. Progress in the development of nonpeptidomimetic BACE 1 inhibitors for Alzheimer’s disease. Curr Med Chem 2009; 16:1806-20.

Huang X, Ling H, Feng L et al. Human leukocyte antigen profile in HIV-1 infected individuals and AIDS patients from Chongqing, China. Microbiol Immunol 2009; 53:512-23.

Huang X, Ling H, Mao W et al. Association of HLA-A, B, DRB1 alleles and haplotypes with HIV-1 infection in Chongqing, China. BMC Infect Dis 2009; 9:201.

Huang X, Tang J, Zhou Q, Lu H, Wu Y, Wu W. Polysaccharide from fuzi (FPS) prevents hypercholesterolemia in rats. Lipids Health Dis 2010; 9:9.

Huang XJ, Ihsan A, Wang X et al. Long-term dose-dependent response of Mequindox on aldosterone, corticosterone and five steroidogenic enzyme mRNAs in the adrenal of male rats. Toxicol Lett 2009; 191:167-73.

Huang Y, Dong G, Hong X, Chai H, Yuan X. Studies on reversing MDR of K562/A02 by ramification of curcumin hydrolyzed. Zhongguo Zhong Yao Za Zhi 2010; 35:2460-3.

Huang Y, Okochi H, May BC et al. Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos 2006; 34:1136-44.

Huang Y, Weisgraber KH, Mucke L, Mahley RW. Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer’s disease. J Mol Neurosci 2004; 23:189-204.

Huang Y, Yang H, Borg BB et al. A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci USA 2007; 104:985-90.

Huang Y, Yin HJ, Ma XJ et al. Correlation between Fc γ R III a and aortic atherosclerotic plaque destabilization in ApoE knockout mice and intervention effects of effective components of Chuanxiong Rhizome and Red Peony Root. Chin J Integr Med 2011; 17:355-60.

Huang Y, Zheng L, Halliday G et al. Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer’s disease. Curr Alzheimer Res 2011; 8:765-70.

Huang YF, Chen ML, Liou SH, Chen MF, Uang SN, Wu KY. Association of CYP2E1, GST and mEH genetic polymorphisms with urinary acrylamide metabolites in workers exposed to acrylamide. Toxicol Lett 2011; 203:118-26.

Huang YT, Onose J, Abe N, Yoshikawa K. In vitro inhibitory effects of pulvinic acid derivatives isolated from Chinese Edible mushrooms, Boletus calopus and Suillus bovinus, on cytochrome P450 activity. Biosci Biotechnol Biochem 2009; 73:855-60.

Huang YW, Hu CY, Chen CL et al. Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus. J Med Virol 2009; 81:588-93.

Huang YY, Oquendo MA, Friedman JM et al. Substance abuse disorder and major depression are associated with the human 5-HT1B receptor gene (HTR1B) G861C polymorphism. Neuropsychopharmacology 2003; 28:163-9.

Huang Z. Impact of Impurities on IC(50) Values of P450 Inhibitors. Drug Metab Lett 2011; 5:156-62.

Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 1996; 24:899-905.

Huang Z, Fasco MJ, Kaminsky LS. Alternative splicing of CYP2D mRNA in human breast tissue. Arch Biochem Biophys 1997; 343:101-8.

Huang Z, Guengerich FP, Kaminsky LS. 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis 1998; 19:867-72.

Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000; 59:961-72.

Huang ZH, Gu D, Mazzone T. Oleic acid modulates the post-transcriptional glycosylation of macrophage ApoE to increase its secretion. J Biol Chem 2004; 279:29195-201.

Huang ZL, Qu WM, Eguchi N et al. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci 2005; 8:858-9.

Hubacek JA, Adámková V, Prusikova M et al. Impact of apolipoprotein A5 variants on statin treatment efficacy. Pharmacogenomics 2009; 10:945-50.

Hubácek JA, Adámková V, Vrablík M et al. Apolipoprotein A5 in health and disease. Physiol Res 2009; 58 Suppl 2:101-9.

Hubacek JA, Bobkova D. Role of cholesterol 7alpha-hydroxylase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol lowering. Mol Diagn Ther 2006; 10:93-100.

Hubacek JA, Vrablik M. Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events. Drug Metabol Drug Interact 2011; 26:13-20.

Hudis CA. Trastuzumab mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51.

Hudson G, Deschauer M, Taylor RW et al. POLG1, C10ORF2, and ANT1 mutations are uncommon in sporadic progressive external ophthalmoplegia with multiple mitochondrial DNA deletions. Neurology 2006; 66:1439-41.

Hue NT, Charlieu JP, Chau TT et al. Glucose-6-phosphate dehydrogenase (G6PD) mutations and haemoglobinuria syndrome in the Vietnamese population. Malar J 2009; 8:152.

Huerta C, Alvarez V, Mata IF et al. Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer’s and Parkinson’s disease. Neurosci Lett 2004; 370:151-4.

Huettner CS, Zhang P, van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000; 24:57-60.

Huezo-Diaz P, Perroud N, Spencer E et al. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol 2011. doi:10. 1177/0269881111414451.

Hüffmeier U, Lascorz J, Böhm B et al. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol 2009; 129:355-8.

Hughes A, Mann D, Pickering-Brown S. Tau haplotype frequency in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Exp Neurol 2003; 181:12-6.

Hughes AL, Powell DW, Bard M et al. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab 2007; 5:143-9.

Hughes AN, O’Brien ME, Petty WJ et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009; 27:1220-6.

Hughes AR, Spreen WR, Mosteller M et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J 2008; 8:365-74.

Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci 2010; 113:315-24.

Hughes LB, Beasley TM, Patel H et al. Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 2006; 65:1213-8.

Hughes MF. Arsenic methylation, oxidative stress and cancer-is there a link? J Natl Cancer Inst 2009; 101:1660-1.

Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D; CNA106030 Study Team. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat 2008; 7:121-9.

Hughes SJ, Morse MA, Weghorst CM et al. Cytochromes P450 are expressed in proliferating cells in Barrett’s metaplasia. Neoplasia 1999; 1:145-53.

Huhtaniemi IT, Pye SR, Holliday KL et al. Effect of polymorphisms in selected genes involved in pituitary-testicular function on reproductive hormones and phenotype in aging men. J Clin Endocrinol Metab 2010; 95:1898-908.

Hui Y, Yu-Yuan L, Yu-Qiang N et al. Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. Liver Int 2008; 28:385-92.

Hui-Chen L, Yang Y, Na W, Ming D, Jian-Fang L, Hong-Yuan X. Pharmacokinetics of the enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in healthy male and female chinese volunteers. Chirality 2004; 16:112-8.

Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 2005; 116:824-9.

Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 2001; 59:806-13.

Huizinga D, Haberstick BC, Smolen A et al. Childhood maltreatment, subsequent antisocial behavior, and the role of monoamine oxidase A genotype. Biol Psychiatry 2006; 60:677-83.

Hukkanen J, Jacob III P, Peng M, Dempsey D, Benowitz NL. Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol 2010; 69:152-9.

Hukkanen J, Lassila A, Päivärinta K et al. Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 2000; 22:360-6.

Hukkanen J, Mäntylä M, Kangas L et al. Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium. Pharmacol Toxicol 1998; 82:93-7.

Hukkanen J, Väisänen T, Lassila A et al. Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther 2003; 304:745-52.

Hulbert AJ, Turner N, Storlien LH, Else PL. Dietary fats and membrane function: implications for metabolism and disease. Biol Rev Camb Philos Soc 2005; 80:155-69.

Hulgan T, Tebas P, Canter JA et al. AIDS Clinical Trials Group 384 and A5005s Study Teams. Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis 2008; 197:858-66.

Hulot JS, Bura A, Villard E et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108:2244-7.

Hulot JS, Collet JP, Silvain J et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56:134-43.

Hum M, McLaughlin BE, Roman G, Vlahakis JZ, Szarek WA, Nakatsu K. The effects of azole-based heme oxygenase inhibitors on rat cytochromes P450 2E1 and 3A1/2 and human cytochromes P450 3A4 and 2D6. J Pharmacol Exp Ther 2010; 334:981-7.

Humbert M, Deng Z, Simonneau G et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002; 20:518-23.

Hume GE, Fowler EV, Lincoln D et al. Angiotensinogen and transforming growth factor beta-1: novel genes in the pathogenesis of Crohn’s disease. J Med Genet 2006; 43:51.

Hummel I, Klappe K, Ercan C, Kok JW. Multidrug resistance-related protein 1 (MRP1) function and localization depend on cortical actin. Mol Pharmacol 2011; 79:229-40.

Hummers-Pradier E, Hess S, Adham IM, Papke T, Pieske B, Kochen MM. Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol 2003; 59:213-9.

Humphries SE, Luong LA, Talmud PJ et al. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial. Atherosclerosis 1998; 139:49-56.

Humphries SE, Martin S, Cooper J, Miller G. Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann Hum Genet 2002; 66:343-52.

Humphries SE, Ye S, Talmud P, Bara L, Wilhelmsen L, Tiret L. European atherosclerosis research study: genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Evidence for gender-genotype-environment interaction. Arterioscler Thromb Vasc Biol 1995; 15:96-104.

Hunfeld NG, Mathot RA, Touw DJ et al. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol 2008; 65:752-60.

Hunfeld NG, Valkhoff VE, Touw DJ, Sturkenboom MC, Kuipers EJ. Clopidogrel and proton pump inhibitors: insufficient evidence of interaction. Ned Tijdschr Geneeskd 2011; 155:2404.

Hung CC, Chen CC, Lin CJ, Liou HH. Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics 2008; 18:390-402.

Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit 2004; 26:534-40.

Hung CC, Liou HH. YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway. Invest New Drugs 2011; 29:1337-46.

Hung IF, Wu AK, Cheng VC et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis 2005; 41:291-300.

Hung RJ, McKay JD, Gaborieau V et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008; 452:633-7.

Hung SI, Chung WH, Jee SH et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16:297-306.

Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102:4134-9.

Hung TT, Wang H, Kingsley EA, Risbridger GP, Russell PJ. Molecular profiling of bladder cancer: Involvement of the TGF-beta pathway in bladder cancer progression. Cancer Lett 2008; 1:27-38.

Hunsaker MR, Wenzel HJ, Willemsen R, Berman RF. Progressive spatial processing deficits in a mouse model of the fragile X premutation. Behav Neurosci 2009; 123:1315-24.

Hunsberger JG, Newton SS, Bennett AH et al. Antidepressant actions of the exercise-regulated gene VGF. Nat Med 2007; 13:1476-82.

Hunt PJ, Marshall SE, Weetman AP, Bell JI, Wass JA, Welsh KI. Cytokine gene polymorphisms in autoimmune thyroid disease. J Clin Endocrinol Metab 2000; 85:1984-8.

Huo H, Magro PG, Pietsch EC, Patel BB, Scotto KW. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer Res 2010; 70:8726-35.

Huriletemuer H, Zhang C, Niu G, Zhao S, Hurile H. Gene polymorphisms and related risk factors in Mongolian hypertensive stroke patients. Neurosciences 2010; 15:184-9.

Hurley DM, Accili D, Stratakis CA et al. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest 1991; 87:680-6.

Huskey SW, Dean DC, Miller RR, Rasmusson GH, Chiu SH. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos 1995; 23:1126-35.

Hussein YM, Gharib AF, Etewa RL, Elsawy WH. Association of L55M and Q192R polymorphisms in paraoxonase 1 (PON1) gene with breast cancer risk and their clinical significance. Mol Cell Biochem 2011; 351:117-23.

Hustert E, Zibat A, Presecan-Siedel E et al. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 2001; 29:1454-9.

Hutchins G, Southward K, Handley K et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29:1261-70.

Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol 2004; 57:287-97.

Hutson JR, Koren G, Matthews SG. Placental P-glycoprotein and breast cancer resistance protein: influence of polymorphisms on fetal drug exposure and physiology. Placenta 2010; 31:351-7.

Hutson PR, Oettel K, Douglas J et al. Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test. Cancer Chemother Pharmacol 2008; 62:373-7.

Hutton M. Molecular genetics of chromsome 17 tauopathies. Ann NY Acad Sci 2000; 920:63-73.

Hutton M. Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanism. Neurology 2001; 56(Suppl 4):21-5.

Hutton M, Lendon CL, Rizzu P et al. Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393:702-5.

Huttunen KM, Mähönen N, Leppänen J et al. Novel cyclic phosphate prodrug approach for cytochrome P450-activated drugs containing an alcohol functionality. Pharm Res 2007; 24:679-87.

Hutzler JM, Linder CD, Melton RJ, Vincent J, Daniels JS. In vitro-In vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-Lipoxygenase. Drug Metab Dispos 2010; 38:1113-21.

Hutzler JM, Melton RJ, Rumsey JM, Schnute ME, Locuson CW, Wienkers LC. Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: Evidence for complex heme interactions. Chem Res Toxicol 2006; 19:1650-9.

Huwait EA, Greenow KR, Singh NN, Ramji DP. A novel role for c-Jun N-terminal kinase and phosphoinositide 3-kinase in the liver X receptor-mediated induction of macrophage gene expression. Cell Signal 2011; 23:542-9.

Huwyler J, Wright MB, Gutmann H, Drewe J. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. Curr Drug Metab 2006; 7:119-26.

Hwahng SH, Ki SH, Bae EJ, Kim HE, Kim SG. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology 2009; 49:1913-25.

Hwang DY, Cho JS, Oh JH et al. Differentially expressed genes in transgenic mice carrying human mutant presenilin-2 (N141I): correlation of selenoprotein M with Alzheimer’s disease. Neurochem Res 2005; 30:1009-19.

Hwang G, Müller F, Rahman MA et al. Fish as bioreactors: transgene expression of human coagulation factor VII in fish embryos. Mar Biotechnol 2004; 6:485-92.

Hwang R, Shinkai T, de Luca V et al. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology 2005; 181:179-87.

Hwang R, Shinkai T, de Luca V et al. Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol 2007; 21:718-27.

Hwang R, Souza RP, Tiwari AK et al. Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. Pharmacogenomics 2011; 12:277-91.

Hwang R, Zai C, Tiwari A et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J 2010; 10:200-18.

Hwang SJ, Jeong YH, Kim IS et al. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2010; 3:450-9.

Hwang SJ, Jeong YH, Kim IS et al. The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Thromb Res 2011; 127:23-8.

Hwang YH, Chen YH, Su YN, Hsu CC, Chen YH, Yuan TH. Genetic polymorphism of As3MT and delayed urinary DMA excretion after organic arsenic intake from oyster ingestion. J Environ Monit 2010; 12:1247-54.

Hwu WL, Wang PJ, Hsiao KJ, Wang TR, Chiou YW, Lee YM. Dopa-responsive dystonia induced by a recessive GTP cyclohydrolase I mutation. Hum Genet 1999; 105:226-30.

Hyland R, Dickins M, Collins C, Jones H, Jones B. Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol 2008; 66:498-507.

Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003; 31:540-7.

Hyland R, Osborne T, Payne A et al. In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol 2009; 67:445-54.

Hyland R, Roe EG, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol 2001; 51:239-48.

Hyman BT, Qiu Z, Rebeck GW, Strickland DK. Alpha-2-macroglobulin enhances the clearance of endogenous soluble beta-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. J Neurochem 1999; 73:1393-8.

Hyman BT, West HL, Rebeck GW et al. Quantitative analysis of senile plaques in Alzheimer’s disease: observation of log-normal size distribution and molecular epidemiology of differences associates with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Nat Acad Sci USA 1995; 92:3586-90.

Hynninen VV, Olkkola KT, Bertilsson L et al. Voriconazole increases while itraconazole decreases plasma meloxicam concentrations. Antimicrob Agents Chemother 2009; 53:587-92.

Hynninen VV, Olkkola KT, Bertilsson L, Kurkinen K, Neuvonen PJ, Laine K. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clin Pharmacol Ther 2008; 83:342-8.

Hynninen VV, Olkkola KT, Leino K et al. Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol 2007; 21:651-6.

Hyodo S, Matsubara K, Kameda K, Matsubara Y. Endometrial injury increases side population cells in the uterine endometrium: a decisive role of estrogen. Tohoku J Exp Med 2011; 224:47-55.

Hyun TS, Rao DS, Saint-Dic D et al. HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phosphoinositides via epsin N-terminal homology domains. J Biol Chem 2004; 279:14294-306.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z